Biotech Industry Financials, Performance and Ratios
-
Industry Score
36.2 /100
Rank 81 out of 131 Industries -
Advance/Decline
161/146
-
No. of Companies307
-
Avg. Market Cap3,723
-
Price to Earning Ratio6.36
-
Price to Earning Growth Ratio0.98
-
Price to Book Ratio15.31
-
Return on Equity60.82
-
Return on Capital Employed-
-
Return on Assets21.72
-
Dividend yield 1 year %0.20 %
-
Net Profit Growth Annual YoY %61.58 %
-
Net Profit Growth Qtr YoY %-171.09 %
-
Net Profit Growth Qtr QoQ %-265.67 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
12,240.7
|
24.5
|
L
 0.3%
H
24
24.7
|
L
 0.0%
H
23.4
25.1
|
L
 -4.7%
H
21.3
28.0
|
L
 -0.3%
H
21.3
28.0
|
L
 41.2%
H
17.1
28.0
|
L
 97.7%
H
8.0
28.0
|
L
 -28.3%
H
7.9
35
|
L
H
7.9
37.6
|
| IQVIA |
|
44,074.9
|
267.8
|
L
 -1.4%
H
262.6
271.8
|
L
 2.1%
H
256.0
271.8
|
L
 14.8%
H
227.2
271.8
|
L
 47.1%
H
162.2
271.8
|
L
 45.0%
H
154.5
271.8
|
L
 19.4%
H
134.6
271.8
|
L
 1.7%
H
134.6
285.6
|
L
 247.9%
H
70.1
285.6
|
| Nuvation Bio Inc (Class A) |
|
2,391.1
|
6.8
|
L
 0.6%
H
6.7
6.9
|
L
 -2.6%
H
6.5
7.1
|
L
 10.6%
H
5.9
7.6
|
L
 44.3%
H
4.5
7.6
|
L
 116.2%
H
3.0
9.8
|
L
 315.2%
H
1.0
9.8
|
L
 -31.2%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,776.7
|
29.7
|
L
 -1.6%
H
29.4
30.1
|
L
 -3.0%
H
28.2
31.5
|
L
 7.4%
H
27.3
31.6
|
L
 24.3%
H
21.8
31.7
|
L
 154.8%
H
11.0
31.7
|
L
 39.9%
H
6.5
31.7
|
L
 -11.3%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
262.2
|
4.6
|
L
 -0.7%
H
4.5
4.7
|
L
 -5.5%
H
4.4
5.0
|
L
 16.2%
H
4.0
5.1
|
L
 6.0%
H
3.4
5.1
|
L
 154.1%
H
1.8
5.5
|
L
 -21.5%
H
1.2
6.3
|
L
 -83.3%
H
1.2
33.0
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
3,703.9
|
11.4
|
L
 -1.2%
H
11.3
11.6
|
L
 -7.8%
H
10.8
12.4
|
L
 96.1%
H
5.6
12.6
|
L
 99.8%
H
5.0
12.6
|
L
 186.5%
H
2.7
12.6
|
L
 104.5%
H
1.9
12.6
|
L
 -39.0%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Absci Corp |
|
1,513.6
|
8.8
|
L
 0.2%
H
8.7
9.0
|
L
 -6.4%
H
8.4
9.3
|
L
 11.2%
H
8.1
10.0
|
L
 48.5%
H
5.9
12.1
|
L
 270.6%
H
2.2
12.1
|
L
 371.7%
H
1.1
12.1
|
L
 -56.1%
H
1.1
20.9
|
L
H
1.1
31.5
|
| Adma Biologics Inc |
|
2,154.7
|
9.6
|
L
 0.4%
H
9.4
9.6
|
L
 1.5%
H
9.2
9.6
|
L
 10.1%
H
8.7
10.4
|
L
 24.0%
H
7.8
10.4
|
L
 -43.1%
H
7.2
20.5
|
L
 147.3%
H
3.1
25.7
|
L
 623.3%
H
1.0
25.7
|
L
 66.1%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
3,875.0
|
24.3
|
L
 -1.2%
H
23.9
24.4
|
L
 -8.2%
H
23.8
26.6
|
L
 5.1%
H
23.0
26.9
|
L
 -62.0%
H
20.9
91.2
|
L
 -52.8%
H
20.9
91.2
|
L
 -10.9%
H
9.1
91.2
|
L
 -84.6%
H
9.1
160
|
L
H
9.1
285
|
| Agenus Inc |
|
370.9
|
8.2
|
L
H
8.0
8.4
|
L
 5.5%
H
7.5
8.4
|
L
 5.4%
H
6.4
8.9
|
L
 155.9%
H
2.9
8.9
|
L
 93.4%
H
2.7
8.9
|
L
 -70.4%
H
1.4
196
|
L
 -93.1%
H
1.4
196
|
L
 -93.2%
H
1.4
196
|
| Change Agents Corp |
|
2.5
|
2.4
|
L
 -0.4%
H
2.3
2.4
|
L
 -7.6%
H
2.3
4.7
|
L
 -36.7%
H
2.3
4.8
|
L
 -67.6%
H
2.3
7.7
|
L
 -94.2%
H
2.3
58.0
|
L
 -99.2%
H
2.3
1350
|
L
 -99.9%
H
2.3
3450
|
L
H
2.3
40500
|
| Aldeyra Therapeutics Inc |
|
89.3
|
1.5
|
L
H
1.5
1.5
|
L
 -3.9%
H
1.5
1.6
|
L
 -3.3%
H
1.4
1.6
|
L
 -20.4%
H
1.4
2.5
|
L
 -74.6%
H
1.1
5.9
|
L
 -80.4%
H
1.1
7.6
|
L
 -83.9%
H
1.1
12.0
|
L
 -72.4%
H
1.1
16.7
|
| Alector Inc |
|
274.7
|
2.5
|
L
 -2.0%
H
2.4
2.6
|
L
 2.9%
H
2.2
2.8
|
L
 62.9%
H
1.5
2.8
|
L
 38.2%
H
1.4
2.8
|
L
 -11.8%
H
1.1
3.4
|
L
 -55.8%
H
0.9
8.9
|
L
 -90.8%
H
0.9
27.4
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
680.6
|
2.0
|
L
 -0.5%
H
2.0
2.0
|
L
 -5.7%
H
1.9
2.1
|
L
 7.1%
H
1.8
2.2
|
L
 -1.5%
H
1.6
2.3
|
L
 75.9%
H
1.0
4.5
|
L
 -51.4%
H
0.9
5.8
|
L
 -92.3%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
665.3
|
3.4
|
L
 5.9%
H
3.3
3.4
|
L
 5.6%
H
3.0
3.4
|
L
 14%
H
2.8
3.4
|
L
 19.2%
H
2.6
3.4
|
L
 -7.1%
H
2.6
6.4
|
L
 29.1%
H
2.1
14.8
|
L
 -79.2%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,898.3
|
5.3
|
L
 -1.1%
H
5.2
5.4
|
L
 9.0%
H
4.8
5.5
|
L
 40.4%
H
3.7
5.5
|
L
 69.4%
H
3.0
5.5
|
L
 -33.1%
H
2.9
9.3
|
L
 -46.5%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
92.8
|
3.9
|
L
 -1.0%
H
3.8
4.0
|
L
 -4.9%
H
3.8
4.2
|
L
 -3.7%
H
3.8
4.4
|
L
 -17.4%
H
3.0
6.3
|
L
 -14.7%
H
3.0
11.9
|
L
 21.1%
H
0.4
12.9
|
L
 -80.7%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
277.9
|
2.0
|
L
 -1.0%
H
2.0
2.0
|
L
 -2.0%
H
1.9
2.1
|
L
 4.2%
H
1.9
2.2
|
L
 20.4%
H
1.4
2.4
|
L
 97.1%
H
1.0
2.7
|
L
 -55.5%
H
0.4
17.8
|
L
 -97.2%
H
0.4
81.2
|
L
H
0.4
117.5
|
| Amgen |
|
236,380.5
|
437.2
|
L
 -1.6%
H
435
441.9
|
L
 0.1%
H
426
445.8
|
L
 15.4%
H
376.0
447.0
|
L
 29.3%
H
334.1
447.0
|
L
 54.0%
H
269.8
447.0
|
L
 70.3%
H
248.4
447.0
|
L
 93.1%
H
198.6
447.0
|
L
 157.5%
H
133.6
447.0
|
| AnaptysBio Inc |
|
1,681.8
|
56.8
|
L
 -1.2%
H
56.1
58.8
|
L
 -0.9%
H
54.7
58.8
|
L
 5.9%
H
53.4
60.3
|
L
 10.9%
H
49.7
70.9
|
L
 152.1%
H
17.1
73.3
|
L
 188.3%
H
12.2
73.3
|
L
 111.9%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,636.2
|
71.2
|
L
 -1.1%
H
71.1
72.1
|
L
 -3.1%
H
71.1
75.0
|
L
 -11.0%
H
71.1
83.2
|
L
 -5.3%
H
71.1
87.2
|
L
 -25.0%
H
70.2
99.5
|
L
 10.3%
H
48.2
99.5
|
L
 141.5%
H
22.3
99.5
|
L
 19.0%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
104.5
|
3.1
|
L
 0.7%
H
3
3.1
|
L
 -14.7%
H
3.0
3.7
|
L
 -10.0%
H
3.0
3.9
|
L
 21.8%
H
2.3
3.9
|
L
 2.7%
H
2.3
5.5
|
L
 -15.7%
H
2.1
5.5
|
L
 -43.5%
H
2.1
6.5
|
L
 -26.7%
H
0.6
8.1
|
| Aptevo Therapeutics Inc |
|
3.1
|
1.7
|
L
 1.8%
H
1.6
1.8
|
L
 -28.1%
H
1.4
2.8
|
L
 -56.0%
H
1.4
4.2
|
L
 -65.3%
H
1.4
5.1
|
L
 -94.3%
H
1.4
48.8
|
L
 -100.0%
H
1.4
287179.2
|
L
 -100.0%
H
1.4
12940587.7
|
L
 -100.0%
H
1.4
52102512
|
| AquaBounty Tech Inc |
|
5.9
|
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 -12.2%
H
1.1
1.3
|
L
 25%
H
0.9
1.6
|
L
 15%
H
0.9
1.6
|
L
 -1.7%
H
0.8
3.0
|
L
 -77.8%
H
0.5
6.1
|
L
 -98.7%
H
0.5
92.4
|
L
H
0.5
610
|
| Arvinas Inc |
|
614.0
|
9.4
|
L
 0.9%
H
9.2
9.5
|
L
 1.6%
H
9.0
9.7
|
L
 16.5%
H
8.2
9.7
|
L
 22.0%
H
7.0
9.7
|
L
 18.9%
H
7.0
14.5
|
L
 -66.3%
H
5.9
53.1
|
L
 -89.1%
H
5.9
98.7
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
12,195.9
|
86.3
|
L
 -0.2%
H
84.2
87.0
|
L
 -2.5%
H
80.8
88.2
|
L
 0.4%
H
80.8
91.0
|
L
 19.0%
H
69.5
95.5
|
L
 210.6%
H
27.1
95.5
|
L
 208.8%
H
9.6
95.5
|
L
 27.8%
H
9.6
95.5
|
L
 1107.6%
H
1.2
95.5
|
| LeonaBio Inc |
|
71.2
|
7.6
|
L
 -1.8%
H
7.4
7.9
|
L
 -4.2%
H
7.4
8.4
|
L
 1.2%
H
7.3
8.9
|
L
 -12.4%
H
6.7
10.1
|
L
 91.9%
H
3.5
14.2
|
L
 -66.7%
H
2.2
43.0
|
L
 -92.9%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,139.5
|
16.1
|
L
 -0.3%
H
15.9
16.2
|
L
 -2.4%
H
15.9
16.5
|
L
 10.4%
H
14.6
17.8
|
L
 2.6%
H
14.4
19.3
|
L
 34%
H
10.3
19.3
|
L
 70.0%
H
4.7
19.3
|
L
 -8.3%
H
4.1
34.0
|
L
 684.4%
H
2.0
34.0
|
| Aura Biosciences Inc |
|
784.0
|
7.6
|
L
 2.6%
H
7.3
7.6
|
L
 -1.8%
H
7
7.8
|
L
 7.4%
H
7.0
8.4
|
L
 9.9%
H
6.0
8.4
|
L
 19.2%
H
4.7
9.5
|
L
 -27.6%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
601.1
|
30.8
|
L
 2.8%
H
29.7
31.1
|
L
 -16.2%
H
29.0
37.0
|
L
 10.1%
H
27.8
38.9
|
L
 8.2%
H
27.2
39.5
|
L
 88.4%
H
14.4
39.5
|
L
 65.3%
H
1.4
61.1
|
L
 -59.1%
H
1.4
79.4
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,265.6
|
19.9
|
L
 0.3%
H
19.7
20.4
|
L
 -6.5%
H
19.7
22
|
L
 3.9%
H
19.4
25
|
L
 13.1%
H
14.3
25
|
L
 165.3%
H
6.9
28
|
L
 -96.4%
H
6.6
1134.5
|
L
 -97.2%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
265.1
|
2.9
|
L
 0.4%
H
2.8
2.9
|
L
 -8.6%
H
2.8
3.1
|
L
 -3.1%
H
2.8
3.7
|
L
 8.3%
H
2.3
3.7
|
L
 -69.9%
H
2.3
10.4
|
L
 -64.0%
H
2.3
14.4
|
L
 -85.3%
H
2.3
23.7
|
L
 -6.2%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
10,826.1
|
206.7
|
L
 -0.8%
H
205.5
208.5
|
L
 0.2%
H
197.1
210.6
|
L
 -2.1%
H
197.1
223.4
|
L
 -11.5%
H
197.1
260.2
|
L
 69.4%
H
112.9
260.2
|
L
 153.0%
H
55.0
260.2
|
L
 674.4%
H
20.6
260.2
|
L
 2742.9%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -6.8%
H
0.8
1.0
|
L
 -5.8%
H
0.8
1.1
|
L
 -17.2%
H
0.8
1.1
|
L
 -58.8%
H
0.5
2.1
|
L
 -43.8%
H
0.5
2.6
|
L
 -90.2%
H
0.5
9.8
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
22.3
|
11.5
|
L
 5.8%
H
10.2
11.8
|
L
 27.3%
H
8.8
11.8
|
L
 55.8%
H
6.5
11.8
|
L
 -23.4%
H
6.5
16.1
|
L
 -56.2%
H
3.0
49.6
|
L
 -91.4%
H
3.0
176
|
L
 -99.2%
H
3.0
1488
|
L
 -99.8%
H
3.0
17759.8
|
| Argen X SE (ADR) |
|
64,634.9
|
1,033.2
|
L
 -1.9%
H
1031.2
1048.4
|
L
 -2.4%
H
1005.8
1072.8
|
L
 24.4%
H
832.7
1072.8
|
L
 27.1%
H
822
1072.8
|
L
 43.1%
H
661.9
1072.8
|
L
 100.7%
H
327.7
1072.8
|
L
 194.7%
H
249.5
1072.8
|
L
H
17.3
1072.8
|
| BridgeBio Pharma Inc |
|
14,630.7
|
74.8
|
L
 -0.8%
H
74.1
75.4
|
L
 -4.9%
H
74.1
80.6
|
L
 -6.4%
H
74.1
89.5
|
L
 14.3%
H
65.1
93.4
|
L
 44.4%
H
48.8
93.4
|
L
 144.7%
H
21.6
93.4
|
L
 45.0%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioCardia Inc |
|
16.3
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
 -7.7%
H
1.1
1.2
|
L
 30.1%
H
0.9
1.2
|
L
 22.7%
H
0.8
1.8
|
L
 -47.1%
H
0.8
2.3
|
L
 -90.8%
H
0.8
23.3
|
L
 -97.8%
H
0.8
59.4
|
L
 -99.5%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,545.1
|
10.0
|
L
 -1.3%
H
9.9
10.1
|
L
 0.9%
H
9.5
10.2
|
L
 13.1%
H
8.8
10.7
|
L
 20.7%
H
8.1
11.2
|
L
 20.1%
H
6
11.2
|
L
 36.8%
H
4.0
11.3
|
L
 -36.4%
H
4.0
20.0
|
L
 137.1%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
31.1
|
3.6
|
L
 1.1%
H
3.5
3.6
|
L
 -3.8%
H
3.5
3.8
|
L
 6.3%
H
3.3
4.2
|
L
 7.9%
H
2.6
4.2
|
L
 -56.7%
H
2.6
14.7
|
L
 -100.0%
H
2.6
10770
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
80097.7
|
| Black Diamond Therapeutics Inc |
|
121.8
|
2.1
|
L
 1.0%
H
2.1
2.1
|
L
 -6.6%
H
2.0
2.3
|
L
 21.8%
H
1.7
2.3
|
L
 1.0%
H
1.6
2.3
|
L
 -26.4%
H
1.6
4.9
|
L
 -40.4%
H
1.2
7.7
|
L
 -78.4%
H
1.2
10.5
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,063.5
|
29.7
|
L
 0.7%
H
28.9
30.0
|
L
 -2.7%
H
28.0
30.5
|
L
 14.5%
H
25.7
31.5
|
L
 0.4%
H
24.7
38.3
|
L
 58.1%
H
17.7
38.3
|
L
 26.4%
H
13.5
49.5
|
L
 -73.6%
H
13.5
116.9
|
L
H
13
138.5
|
| BioVie Inc |
|
16.9
|
2
|
L
 -1.5%
H
2.0
2.1
|
L
 -8.7%
H
2.0
2.5
|
L
 23.5%
H
0.8
3.8
|
L
 21.2%
H
0.8
3.8
|
L
 19.8%
H
0.8
3.8
|
L
 -99.4%
H
0.8
582
|
L
 -99.7%
H
0.8
1438
|
L
 -99.9%
H
0.8
5625
|
| Biomarin pharma Inc - Registered Shares |
|
12,878.5
|
66.5
|
L
 0.2%
H
65.5
66.6
|
L
 1.9%
H
64.1
67.7
|
L
 10.9%
H
58.9
71.0
|
L
 21.7%
H
54.3
71.0
|
L
 12.8%
H
49.3
71.0
|
L
 -28.5%
H
49.3
99.6
|
L
 -21.7%
H
49.3
117.8
|
L
 -30.5%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
14.1
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -0.8%
H
1.2
1.3
|
L
 7.1%
H
1.1
1.3
|
L
 -7.7%
H
1
1.3
|
L
 -69.1%
H
1
5.5
|
L
 -68.8%
H
0.1
11.6
|
L
 -98.0%
H
0.1
62.8
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
435.6
|
12.7
|
L
 1.9%
H
12.3
12.8
|
L
 0.1%
H
11.7
13.3
|
L
 4.4%
H
11.7
14.0
|
L
 21.9%
H
10
14.3
|
L
 -8.8%
H
9.9
16.8
|
L
 343.4%
H
2.7
17.2
|
L
 -81.0%
H
1.9
81.3
|
L
 -96.9%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.4
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 1.8%
H
1.1
1.2
|
L
 4.5%
H
1.1
1.2
|
L
 -6.5%
H
1.1
1.5
|
L
 -21.6%
H
1.1
3.4
|
L
 -99.3%
H
1.1
173.5
|
L
 -100.0%
H
1.1
3142.5
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
2.2
|
0.1
|
L
 -41.7%
H
0.1
0.1
|
L
 -90.3%
H
0.1
0.2
|
L
 -91.8%
H
0.1
1.2
|
L
 -94.0%
H
0.1
1.5
|
L
 -98.1%
H
0.1
4.3
|
L
 -98.2%
H
0.1
8.1
|
L
 -99.8%
H
0.1
36.5
|
L
H
0.1
71.5
|
| BioNTech SE (ADR) |
|
26,065.0
|
103.8
|
L
 0.9%
H
102.3
104.8
|
L
 -6.9%
H
98.8
105.5
|
L
 12.5%
H
88.2
120.3
|
L
 17.3%
H
85.0
120.3
|
L
 3.3%
H
79.5
124
|
L
 -14.8%
H
76.5
131.5
|
L
 -69.0%
H
76.5
374.9
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
588.3
|
3.5
|
L
 -0.3%
H
3.4
3.6
|
L
 2.7%
H
2.8
3.8
|
L
 29%
H
2.6
3.8
|
L
 -3.1%
H
2.6
3.8
|
L
 121.0%
H
1.4
4.2
|
L
 -73.9%
H
1.0
26.4
|
L
 -68.6%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
977.9
|
12.8
|
L
 -1.5%
H
12.8
13.1
|
L
 -7.1%
H
12.6
13.8
|
L
 26.9%
H
10.1
14
|
L
 45.2%
H
7.9
14
|
L
 150.6%
H
4.4
14
|
L
 956.2%
H
0.7
14.6
|
L
 56.8%
H
0.7
14.8
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
14.8
|
2.2
|
L
 -1.4%
H
2.1
2.3
|
L
 -7.7%
H
2
2.5
|
L
 -42.3%
H
2
4.1
|
L
 -48.9%
H
2
5.8
|
L
 -86.5%
H
2
36
|
L
 -86.5%
H
2
41.9
|
L
 -99.2%
H
2
290.5
|
L
H
2
2651.6
|
| Tvardi Therapeutics Inc |
|
25.5
|
1.9
|
L
 3.2%
H
1.8
1.9
|
L
 6.1%
H
1.7
1.9
|
L
 -5.5%
H
1.7
2.1
|
L
 -35.3%
H
1.5
5.7
|
L
 -93.4%
H
1.5
43.7
|
L
 -97.8%
H
1.5
89.3
|
L
 -99.7%
H
1.5
681.5
|
L
 -99.0%
H
1.5
1067.3
|
| C4 Therapeutics Inc |
|
462.6
|
3.8
|
L
 0.5%
H
3.7
3.8
|
L
 -8.3%
H
3.7
4.1
|
L
 7.4%
H
3.5
4.4
|
L
 -5.1%
H
3.4
5.2
|
L
 46.9%
H
1.7
5.2
|
L
 30.6%
H
1.1
11.9
|
L
 -91.5%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
245.3
|
2.6
|
L
 1.2%
H
2.5
2.6
|
L
 -6.2%
H
2.5
2.7
|
L
 8.8%
H
2.3
2.9
|
L
 18.3%
H
2.0
2.9
|
L
 82.4%
H
1.3
3.2
|
L
 127.2%
H
0.5
3.2
|
L
 -62.7%
H
0.5
7.5
|
L
 -65.0%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
97.9
|
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 15.7%
H
0.9
1.2
|
L
 -27.5%
H
0.9
1.8
|
L
 -56.5%
H
0.6
2.7
|
L
 -34.0%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Celldex Therapeutics Inc |
|
3,116.1
|
39.7
|
L
 0.8%
H
38.9
39.8
|
L
 -1.9%
H
38.7
40.6
|
L
 5.3%
H
37.5
45.1
|
L
 33.3%
H
28.4
45.1
|
L
 68.1%
H
22.1
45.1
|
L
 37.7%
H
14.4
53.2
|
L
 -26.8%
H
14.4
57.2
|
L
 -21.0%
H
1.5
75.3
|
| Co-Diagnostics Inc |
|
8.1
|
1.2
|
L
H
1.1
1.2
|
L
 -7.9%
H
1.1
1.3
|
L
 -21.6%
H
0.9
1.7
|
L
 -77.6%
H
0.9
6.6
|
L
 -88.3%
H
0.9
46.5
|
L
 -96.8%
H
0.9
66.9
|
L
 -99.6%
H
0.9
336
|
L
H
0.9
929.7
|
| Z Squared Inc |
|
156.4
|
3.0
|
L
 -3.0%
H
2.9
3.2
|
L
 -30.3%
H
2.8
4.3
|
L
 -42.6%
H
2.8
5.4
|
L
 -72.4%
H
2.8
16.9
|
L
 -77.0%
H
2.8
21.4
|
L
 -86.1%
H
2.3
27.6
|
L
 -70.2%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
6,031.7
|
34.8
|
L
 -0.5%
H
34.4
35.2
|
L
 -6.3%
H
34.0
36.8
|
L
 -10.6%
H
34.0
43.4
|
L
 7.8%
H
30.9
43.4
|
L
 165.8%
H
11.6
43.7
|
L
 167.8%
H
3.7
43.7
|
L
 321.8%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Coya Therapeutics Inc |
|
111.7
|
4.8
|
L
 4.6%
H
4.5
4.8
|
L
 -2.1%
H
4.4
4.8
|
L
 7.5%
H
4.4
5.3
|
L
 2.6%
H
3.9
6.2
|
L
 -28.9%
H
3.7
7.8
|
L
 34.1%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Caribou Biosciences Inc |
|
168.3
|
1.6
|
L
H
1.6
1.6
|
L
 -5.4%
H
1.5
1.7
|
L
 4.7%
H
1.5
1.8
|
L
 -21.5%
H
1.4
2.2
|
L
 -16.9%
H
1.4
3.5
|
L
 -73.3%
H
0.7
8.3
|
L
 -94.8%
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
257.0
|
2.2
|
L
 1.9%
H
2.1
2.2
|
L
 6.8%
H
1.9
2.2
|
L
 67.9%
H
1.3
2.3
|
L
 96.4%
H
1.0
2.3
|
L
 101.8%
H
0.9
2.3
|
L
 120%
H
0.7
3.1
|
L
 -42.4%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
3.3
|
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 -10%
H
1.3
1.6
|
L
 -73.8%
H
1.3
5.3
|
L
 -86.5%
H
1.3
11.4
|
L
 -96.1%
H
1.3
39
|
L
 -99.4%
H
1.3
349.8
|
L
 -100.0%
H
1.3
3492
|
L
 -100.0%
H
1.3
7440
|
| CorMedix Inc |
|
657.1
|
8.4
|
L
 -0.5%
H
8.3
8.6
|
L
 1.4%
H
8.1
8.7
|
L
 11.7%
H
7.1
9.0
|
L
 2.4%
H
7.1
9.1
|
L
 -38.5%
H
6.1
13.9
|
L
 104.1%
H
2.6
17.4
|
L
 30.5%
H
2.6
17.4
|
L
 -7.9%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,394.5
|
55.8
|
L
 -1.2%
H
55.4
57.2
|
L
 -6.0%
H
55.4
59.4
|
L
 12.6%
H
50.2
62.5
|
L
 7.1%
H
45.9
63.5
|
L
 5.3%
H
44.1
78.5
|
L
 10.4%
H
30.0
91.1
|
L
 -54.3%
H
30.0
124.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
72.7
|
5.2
|
L
 -1.1%
H
5.1
5.4
|
L
 4.0%
H
4.9
5.5
|
L
 -9.4%
H
4.8
5.7
|
L
 -8.3%
H
4.8
7
|
L
 -24.9%
H
4.8
8.7
|
L
 -17.7%
H
3.6
12.0
|
L
 -52.4%
H
3.6
12.0
|
L
 236.8%
H
1.5
17.9
|
| Cue Biopharma Inc |
|
199.3
|
27.4
|
L
 -0.8%
H
27.0
28.0
|
L
 -2.6%
H
25.0
29.8
|
L
 2.1%
H
22.6
34.6
|
L
 2.0%
H
22.6
45.5
|
L
 15.3%
H
5.0
45.5
|
L
 -65.9%
H
5.0
97.5
|
L
 -92.3%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
4.4
|
1.2
|
L
 -4.7%
H
1.2
1.3
|
L
 -21.8%
H
1.2
2.3
|
L
 -37.8%
H
1.2
2.3
|
L
 -70.9%
H
1.2
4.6
|
L
 -90.5%
H
1.2
14.6
|
L
 37.1%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
19.9
|
2.7
|
L
 -4.2%
H
2.7
2.9
|
L
 -0.4%
H
2.6
2.9
|
L
 67.3%
H
1.6
3.0
|
L
 57.6%
H
1.4
3.0
|
L
 -10.3%
H
1.4
3.6
|
L
 -40.6%
H
1.4
10.2
|
L
 -95.4%
H
1.4
61.4
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,837.6
|
13.3
|
L
 -0.2%
H
13.1
13.4
|
L
 -9.4%
H
12.7
14.7
|
L
 18.0%
H
11.2
15.0
|
L
 4.6%
H
10.6
15.4
|
L
 181.7%
H
4.7
15.4
|
L
 42.2%
H
2.3
15.4
|
L
 -60.1%
H
2.3
49.5
|
L
H
2.3
61.7
|
| DiaMedica Therapeutics Inc |
|
364.0
|
6.8
|
L
 2.9%
H
6.5
6.9
|
L
H
6.2
6.9
|
L
 3.5%
H
6.2
7.2
|
L
 19.5%
H
5.2
8.5
|
L
 27.4%
H
5.2
10.4
|
L
 120.6%
H
1.9
10.4
|
L
 64.6%
H
1.1
10.4
|
L
 71.3%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,561.4
|
22.3
|
L
 -2.3%
H
22.1
22.5
|
L
 -9.7%
H
22.1
24.6
|
L
 -3.8%
H
22.1
25.7
|
L
 13.3%
H
19.2
27.3
|
L
 45.5%
H
12.6
27.3
|
L
 -4.4%
H
10.6
33.3
|
L
 -59.1%
H
10.6
56.2
|
L
H
10.6
93.9
|
| Bright Minds Biosciences Inc |
|
639.4
|
65.2
|
L
 -4.2%
H
64.5
69.1
|
L
 -12.6%
H
64.5
74.3
|
L
 -11.7%
H
64.5
87
|
L
 -12.4%
H
56.5
87
|
L
 50.6%
H
39.7
123.8
|
L
 2889.0%
H
0.9
123.8
|
L
 134.8%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
947.5
|
15.1
|
L
 0.7%
H
15.0
15.4
|
L
 -0.7%
H
14.4
15.8
|
L
 18.7%
H
12.6
16.1
|
L
 45.0%
H
10.1
16.1
|
L
 154.0%
H
5.3
17.3
|
L
 510.5%
H
2.0
17.3
|
L
 -14.5%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
206.2
|
7.5
|
L
 1.4%
H
7.3
7.6
|
L
 -11.1%
H
7.2
8.4
|
L
 5.8%
H
7
9.3
|
L
 23.7%
H
6.0
9.6
|
L
 47.9%
H
3.5
9.6
|
L
 1424.5%
H
0.3
19.4
|
L
 -44.6%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
4,534.2
|
24.3
|
L
 -2.7%
H
24.1
24.7
|
L
 -6.9%
H
24.1
26.2
|
L
 -3.8%
H
24.1
27.3
|
L
 35.0%
H
16.6
27.3
|
L
 80.1%
H
11.9
27.3
|
L
 106.3%
H
6.4
47.5
|
L
 46.0%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
496.1
|
3.2
|
L
 4.9%
H
3.0
3.2
|
L
 -2.1%
H
3.0
3.4
|
L
 21.9%
H
2.6
3.5
|
L
 16.2%
H
2.4
3.8
|
L
 29.2%
H
1.7
4.5
|
L
 -64.4%
H
0.9
11.7
|
L
 -95.3%
H
0.9
72.5
|
L
 -80.0%
H
0.9
100.0
|
| Eloxx Pharma |
|
51.5
|
15
|
L
 5.7%
H
14.1
16.5
|
L
 -6.3%
H
13.8
17.3
|
L
 -18.7%
H
13.8
23.4
|
L
 268.6%
H
8.2
23.4
|
L
 268.6%
H
8.2
23.4
|
L
 177.8%
H
0
23.4
|
L
 -76.0%
H
0
75.6
|
L
 -90.6%
H
0
984
|
| Elicio Therapeutics Inc |
|
63.3
|
2.4
|
L
 -3.6%
H
2.4
2.5
|
L
 -19.7%
H
2.4
3
|
L
 -15.7%
H
2.4
3.4
|
L
 -80.8%
H
2.4
16
|
L
 -76.7%
H
2.4
16
|
L
 -69.5%
H
2.4
16
|
L
 -98.1%
H
2.4
136.6
|
L
H
2.4
263
|
| Enliven Therapeutics Inc |
|
4,346.4
|
59.3
|
L
 -0.6%
H
59.0
59.9
|
L
 -2.0%
H
56.3
61.2
|
L
 2.2%
H
56.3
62.3
|
L
 64.6%
H
33.5
62.3
|
L
 183.2%
H
14.8
62.3
|
L
 261.9%
H
9.8
62.3
|
L
 194.8%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
891.4
|
15.5
|
L
 6.4%
H
14.3
16.0
|
L
 3.1%
H
13.1
16.0
|
L
 31.4%
H
12.1
18.3
|
L
 48.7%
H
10.2
18.3
|
L
 536.1%
H
1.5
18.3
|
L
 485.7%
H
1.1
18.3
|
L
 -43.7%
H
1.1
29.5
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
19.2
|
1.1
|
L
 -5.2%
H
1.0
1.2
|
L
 -25.7%
H
1.0
1.6
|
L
 -49.3%
H
1.0
2.3
|
L
 29.4%
H
0.4
7.6
|
L
 3.8%
H
0.4
7.6
|
L
 -53.2%
H
0.4
7.6
|
L
 -90.6%
H
0.4
11.9
|
L
 -98.4%
H
0.4
74.8
|
| Enochian Biosciences Inc |
|
-
|
2.4
|
L
 1.7%
H
2.3
2.4
|
L
 1.7%
H
2.2
2.5
|
L
H
2.1
3.2
|
L
 -16.7%
H
1.9
5.0
|
L
 986.4%
H
0.1
5.0
|
L
 646.9%
H
0.1
5.0
|
L
 -69.2%
H
0.1
13.8
|
L
 218.7%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
9.0
|
0.5
|
L
 4.6%
H
0.4
0.5
|
L
 15%
H
0.4
0.5
|
L
 64.3%
H
0.3
1.0
|
L
 76.9%
H
0.2
1.0
|
L
 -78.8%
H
0.2
2.8
|
L
 -74.4%
H
0.1
9.9
|
L
 -99.9%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
140.1
|
2.2
|
L
 -0.5%
H
2.2
2.3
|
L
 -9.8%
H
2.2
2.5
|
L
 0.5%
H
2.0
2.6
|
L
 -28.9%
H
2.0
3.5
|
L
 18.2%
H
0.8
3.5
|
L
 179.7%
H
0.3
3.5
|
L
 -63.3%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Evogene Ltd |
|
8.5
|
0.5
|
L
H
0.5
0.5
|
L
H
0.5
0.6
|
L
H
0.5
0.8
|
L
 -10%
H
0.4
0.8
|
L
 -56.5%
H
0.4
1.5
|
L
 -92.8%
H
0.4
10.4
|
L
 -98.3%
H
0.4
34.2
|
L
 -99.2%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,677.6
|
43.1
|
L
 2.7%
H
41.6
43.4
|
L
 -2.5%
H
40.6
44.2
|
L
 12.2%
H
40.6
46.6
|
L
 19.0%
H
30.8
48.4
|
L
 194.2%
H
13.7
48.4
|
L
 567.8%
H
5.1
48.4
|
L
 158.4%
H
5.1
48.4
|
L
H
5.1
48.4
|
| Evaxion Biotech A/S (ADR) |
|
26.0
|
3.1
|
L
 1.3%
H
3.1
3.2
|
L
 -1.0%
H
2.9
3.2
|
L
 11.8%
H
2.8
3.6
|
L
 -11.9%
H
2.8
4.0
|
L
 20.5%
H
2.5
12.2
|
L
 -61.5%
H
0.8
13.6
|
L
 -96.2%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
297.2
|
2.5
|
L
 2.5%
H
2.4
2.5
|
L
 -2.4%
H
2.3
2.5
|
L
 -0.8%
H
2.2
2.9
|
L
 11.7%
H
1.8
3.2
|
L
 148%
H
0.9
3.2
|
L
 -11.7%
H
0.7
8.8
|
L
 -96.6%
H
0.7
75.8
|
L
 4.2%
H
0.7
121.2
|
| 4D Molecular Therapeutics Inc |
|
827.0
|
15.0
|
L
 1.8%
H
14.3
15
|
L
 0.4%
H
13.7
15.1
|
L
 48.4%
H
10.1
16.9
|
L
 57.1%
H
8.4
16.9
|
L
 131.4%
H
6.1
16.9
|
L
 -9.6%
H
2.2
36.3
|
L
 -53.5%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
434.5
|
12.4
|
L
 -1.3%
H
12.3
12.6
|
L
 5.3%
H
11.6
12.8
|
L
 29.2%
H
9.6
13.3
|
L
 35.6%
H
8.5
13.3
|
L
 39.8%
H
5.7
13.3
|
L
 48.0%
H
4.0
13.3
|
L
 56.0%
H
3.8
13.3
|
L
 507.4%
H
1.6
15.0
|
| Foghorn Therapeutics Inc |
|
292.2
|
4.9
|
L
 1.0%
H
4.7
5
|
L
 -20.9%
H
4.7
6.2
|
L
 6.7%
H
4.6
7.6
|
L
 35.2%
H
3.6
7.6
|
L
 -6.6%
H
3.3
7.6
|
L
 -36.6%
H
2.7
10.2
|
L
 -64.0%
H
2.7
24.3
|
L
H
2.7
28.3
|
| First Wave BioPharma Inc |
|
5.1
|
3.3
|
L
 9.4%
H
3.1
3.5
|
L
 -19.0%
H
2.8
4.2
|
L
 11.7%
H
2.7
4.3
|
L
 -45.2%
H
2.6
6.5
|
L
 17.3%
H
1.9
6.9
|
L
 -44.0%
H
0.4
22.2
|
L
 -100.0%
H
0.4
29609.8
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
464.9
|
4.6
|
L
 6.0%
H
4.3
4.7
|
L
 11.4%
H
3.9
4.7
|
L
 52.2%
H
2.7
4.7
|
L
 96.2%
H
2.3
5.6
|
L
 2.7%
H
2.0
7.1
|
L
 161.9%
H
0.7
7.1
|
L
 19.7%
H
0.7
7.1
|
L
 171.2%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
78.6
|
1.8
|
L
 -1.1%
H
1.8
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 2.9%
H
1.7
2.4
|
L
 0.6%
H
1.6
2.4
|
L
 -6.3%
H
1.5
4.3
|
L
 -46.3%
H
0.9
5.3
|
L
 -76.8%
H
0.9
9.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
10.2
|
0.9
|
L
 -2.3%
H
0.9
0.9
|
L
 -9.5%
H
0.8
0.9
|
L
 -6.5%
H
0.8
1.0
|
L
 -27.1%
H
0.7
1.3
|
L
 -55.9%
H
0.7
3.7
|
L
 -75.3%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
1,008.7
|
1.6
|
L
 4.0%
H
1.5
1.6
|
L
 2.6%
H
1.5
1.6
|
L
 22.7%
H
1.3
1.7
|
L
 35.3%
H
1.1
1.7
|
L
 12.1%
H
1.0
2.0
|
L
 -36.7%
H
1.0
5.3
|
L
 9.0%
H
1.0
5.3
|
L
 -42.9%
H
0.8
7.0
|
| Gilead Sciences |
|
187,233.2
|
151
|
L
 -0.2%
H
149.2
151.2
|
L
 1.4%
H
143.2
152.6
|
L
 15.1%
H
129.0
152.6
|
L
 17.1%
H
121.4
152.6
|
L
 33.6%
H
108.5
157.3
|
L
 97.0%
H
62.1
157.3
|
L
 109.8%
H
57.2
157.3
|
L
 96.4%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
234.1
|
16.0
|
L
 2.1%
H
15.5
16.0
|
L
 -14.8%
H
14.3
18.9
|
L
 17.8%
H
13.2
19.6
|
L
 -34.3%
H
12.5
25.5
|
L
 38.3%
H
7.8
34.1
|
L
 72.8%
H
7.6
34.1
|
L
 -63.7%
H
6.8
48.5
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,180.7
|
13.8
|
L
 -3.8%
H
13.8
14.3
|
L
 -3.4%
H
13.1
15
|
L
 -10.0%
H
13.1
16.9
|
L
 -21.3%
H
13.1
25.2
|
L
 176.8%
H
4.8
25.8
|
L
 123.2%
H
2.4
25.8
|
L
 -67.2%
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
2.5
|
0.5
|
L
 -5.9%
H
0.5
0.5
|
L
 -33.3%
H
0.5
0.7
|
L
 -33.3%
H
0.5
0.9
|
L
 -76.4%
H
0.5
2.2
|
L
 -97.4%
H
0.5
19.2
|
L
 -99.8%
H
0.5
276.8
|
L
 -100.0%
H
0.5
2130
|
L
 -100.0%
H
0.5
379518072.3
|
| GRI Bio Inc |
|
6.3
|
2.9
|
L
 25.8%
H
2.3
3.4
|
L
 39.1%
H
1.8
3.4
|
L
 100%
H
1.4
3.4
|
L
 43.3%
H
1.4
3.4
|
L
 -93.0%
H
1.4
80.4
|
L
 -100.0%
H
1.4
77102.5
|
L
 -100.0%
H
1.4
13462627.3
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
347.1
|
6.0
|
L
 2.2%
H
5.6
6.0
|
L
 23.9%
H
4.7
6.0
|
L
 19.2%
H
4.5
6.7
|
L
 -15.0%
H
4.5
7.4
|
L
 -84.8%
H
4.5
50.4
|
L
 -94.6%
H
4.5
413
|
L
 -99.4%
H
4.5
1031.9
|
L
H
4.5
1666
|
| Galapagos NV (ADR) |
|
1,877.4
|
28.5
|
L
 -1.8%
H
28.4
29.0
|
L
 -3.2%
H
28.3
29.5
|
L
 6.5%
H
25.7
29.9
|
L
 3.6%
H
25.7
30.9
|
L
 -8.9%
H
25.7
37.8
|
L
 -25.1%
H
22.4
42.5
|
L
 -52.7%
H
22.4
72.1
|
L
 -47.6%
H
22.4
274.0
|
| Genmab (ADR) |
|
20,651.3
|
33.6
|
L
 -2.4%
H
33.5
34.2
|
L
 -1.5%
H
32.5
34.7
|
L
 17.2%
H
28.5
34.7
|
L
 40.7%
H
24.1
34.7
|
L
 24.1%
H
23.6
35.4
|
L
 -12.5%
H
17.2
38.8
|
L
 -31.0%
H
17.2
48.0
|
L
 112.8%
H
12.1
49.1
|
| Halozyme Therapeutics Inc |
|
12,506.3
|
110.2
|
L
 -0.5%
H
109
111.2
|
L
 3.1%
H
103.5
111.2
|
L
 33.9%
H
81.8
111.2
|
L
 57.8%
H
67.0
111.2
|
L
 47.3%
H
61.2
111.2
|
L
 157.3%
H
32.8
111.2
|
L
 161.0%
H
29.9
111.2
|
L
 1018.7%
H
8.2
111.2
|
| HCW Biologics Inc |
|
5.4
|
2.9
|
L
 2.4%
H
2.8
3.0
|
L
 -7.3%
H
2.7
3.8
|
L
 -12.0%
H
2.1
3.8
|
L
 -70.8%
H
2.1
10.4
|
L
 -89.8%
H
1.5
36.7
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
26.8
|
2.3
|
L
 1.3%
H
2.2
2.3
|
L
 -3.0%
H
2.0
2.4
|
L
 14%
H
1.8
2.4
|
L
 -6.9%
H
1.8
3.8
|
L
 -52.2%
H
1.8
6.9
|
L
 -62.1%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
64.5
|
0.3
|
L
 3.0%
H
0.3
0.4
|
L
 3.0%
H
0.3
0.4
|
L
 -33.3%
H
0.3
0.5
|
L
 -24.4%
H
0.3
0.5
|
L
 -74.4%
H
0.3
1.6
|
L
 -78.3%
H
0.3
3.9
|
L
 -97.1%
H
0.3
12.9
|
L
 -98.1%
H
0.3
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
0.0
|
3.2
|
L
 9.8%
H
3.0
3.3
|
L
 3.5%
H
2.9
3.3
|
L
 6.2%
H
2.7
4.2
|
L
 -33.6%
H
2.7
5.1
|
L
 -79.4%
H
2.1
21
|
L
 -96.1%
H
2.1
109.2
|
L
 -97.2%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
166.7
|
0.6
|
L
H
0.6
0.6
|
L
 -13.0%
H
0.6
0.7
|
L
 -13.0%
H
0.5
0.8
|
L
 -57.1%
H
0.5
1.5
|
L
 -58.9%
H
0.5
2.6
|
L
 -85.1%
H
0.5
10.0
|
L
 -95.7%
H
0.5
17.0
|
L
H
0.5
17.5
|
| Immucell Corp |
|
89.9
|
9.9
|
L
 -1%
H
9.8
10.0
|
L
 -1.2%
H
9.8
10.3
|
L
 -10.3%
H
9.6
11.4
|
L
 -1.5%
H
9.3
12.1
|
L
 51.6%
H
4.5
12.1
|
L
 117.1%
H
3.3
12.1
|
L
 8.8%
H
3.3
12.1
|
L
 36.4%
H
3.3
13.2
|
| InflaRx N.V. |
|
327.2
|
2.2
|
L
 -0.5%
H
2.2
2.4
|
L
 -2.2%
H
2.1
2.4
|
L
 26.9%
H
1.7
2.5
|
L
 7.8%
H
1.5
2.6
|
L
 28.3%
H
0.8
3.0
|
L
 -46.5%
H
0.7
4.3
|
L
 -14.3%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
55.1
|
4.9
|
L
 -0.6%
H
4.7
5.0
|
L
 -9.0%
H
4.7
5.5
|
L
 -14.0%
H
4.7
6.2
|
L
 -11.0%
H
4.7
6.3
|
L
 -64.7%
H
3.9
13.4
|
L
 -91.6%
H
3.9
59.3
|
L
 -97.1%
H
3.9
210
|
L
H
3.9
451.3
|
| Immunome Inc |
|
3,039.3
|
26.8
|
L
 -1.5%
H
26.7
27.1
|
L
 -7.3%
H
26.6
28.8
|
L
 16.3%
H
23.1
30.1
|
L
 35.1%
H
17.8
30.1
|
L
 161.1%
H
8.7
30.1
|
L
 309.2%
H
5.2
31.0
|
L
 77.2%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.9
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 -1.3%
H
1.5
1.7
|
L
H
1.5
1.7
|
L
 -24.8%
H
1.5
2.2
|
L
 -72.4%
H
1.5
6.0
|
L
 -91.4%
H
1.5
54.8
|
L
 -99.3%
H
1.5
252
|
L
 -100.0%
H
1.5
4346.0
|
| Immunovant Inc |
|
8,107.2
|
39.3
|
L
 0.3%
H
38.7
39.7
|
L
 -10.4%
H
38.6
43.4
|
L
 1.9%
H
38.0
45.4
|
L
 26%
H
30.2
45.4
|
L
 135.0%
H
14.6
45.4
|
L
 63.6%
H
12.7
45.6
|
L
 335.6%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
11.8
|
1.2
|
L
 3.5%
H
1.2
1.2
|
L
 15.4%
H
1.0
1.2
|
L
 25%
H
0.9
1.3
|
L
 -22.1%
H
0.9
1.6
|
L
 -46.0%
H
0.9
2.7
|
L
 13.2%
H
0.1
4.2
|
L
 -85.6%
H
0.1
9.5
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
5,740.8
|
121.2
|
L
 -0.9%
H
120.5
124.2
|
L
 -2.2%
H
119.4
129.9
|
L
 46.5%
H
80.4
131.0
|
L
 27.3%
H
77.5
131.0
|
L
 335.9%
H
26.2
155.3
|
L
 437.3%
H
10.8
155.3
|
L
 285.9%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
59.4
|
11.6
|
L
 3.7%
H
11.2
11.6
|
L
 -0.3%
H
10.8
11.8
|
L
 8.9%
H
10.7
12.2
|
L
 -8.8%
H
10.2
13.4
|
L
 -17.3%
H
8.5
17.0
|
L
 -20.3%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
67.7
|
2.4
|
L
 7.5%
H
2.2
2.5
|
L
 1.7%
H
2.2
2.5
|
L
 31.9%
H
1.8
2.5
|
L
 84.9%
H
1.2
2.5
|
L
 23.9%
H
1.1
2.5
|
L
 -70.8%
H
1.1
14.7
|
L
 -90.8%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
3,981.6
|
8.8
|
L
 1.0%
H
8.6
8.9
|
L
 6.4%
H
7.7
8.9
|
L
 103.5%
H
4.3
9.4
|
L
 131.9%
H
3.7
9.4
|
L
 297.7%
H
1.8
9.4
|
L
 42.9%
H
1.6
18.3
|
L
 -65.0%
H
1.6
28.0
|
L
 10.3%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
62.0
|
1.3
|
L
 -0.8%
H
1.3
1.4
|
L
 -7.0%
H
1.3
1.4
|
L
 -2.2%
H
1.3
1.5
|
L
 -26.7%
H
1.1
1.9
|
L
 -33.7%
H
1.0
3.0
|
L
 -35.0%
H
0.3
3.3
|
L
 -81.7%
H
0.3
7.3
|
L
 6500%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
382.1
|
2.1
|
L
 1.0%
H
2.1
2.2
|
L
 -5.4%
H
2.0
2.3
|
L
 6.6%
H
1.9
2.3
|
L
 1.9%
H
1.9
2.6
|
L
 348.9%
H
0.4
3.0
|
L
 -14.6%
H
0.3
5.5
|
L
 -92.2%
H
0.3
30.3
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
3,041.9
|
79.2
|
L
 -0.2%
H
78.1
80.0
|
L
 -4.0%
H
75.9
82.7
|
L
 3.8%
H
74.5
83.6
|
L
 12.6%
H
64.7
83.6
|
L
 28.6%
H
40
99.5
|
L
 50.9%
H
25.6
99.5
|
L
 50.1%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
244.6
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 -7.8%
H
0.8
1.0
|
L
 50.9%
H
0.6
1.1
|
L
 -24.6%
H
0.5
1.2
|
L
 -20.2%
H
0.5
3.1
|
L
 -54.6%
H
0.4
5.2
|
L
 -98.0%
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,860.6
|
36.1
|
L
 -3.8%
H
36.0
37.4
|
L
 -1.7%
H
35.5
38.0
|
L
 11.4%
H
32.0
38.0
|
L
 26.1%
H
27.6
38.0
|
L
 2.4%
H
27.6
40.7
|
L
 -36.9%
H
23.2
77.0
|
L
 9.0%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
53.1
|
0.4
|
L
H
0.4
0.4
|
L
 -5.3%
H
0.4
0.4
|
L
 -5.3%
H
0.4
0.4
|
L
 -12.2%
H
0.4
0.5
|
L
 -77.9%
H
0.3
3.5
|
L
 -81.3%
H
0.3
3.5
|
L
 -91.8%
H
0.3
5
|
L
 -87.3%
H
0.3
8.0
|
| Inventiva (ADR) |
|
1,129.2
|
4.8
|
L
 -1.2%
H
4.6
4.9
|
L
 -2.5%
H
4.5
5.1
|
L
 12.5%
H
4.2
5.1
|
L
 18.3%
H
3.4
5.1
|
L
 -17.2%
H
3.4
8.0
|
L
 30.6%
H
1.5
8.0
|
L
 -65.4%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
1,237.4
|
20.2
|
L
 2.2%
H
19.6
20.3
|
L
 7.8%
H
17.7
20.3
|
L
 32.1%
H
15.3
20.3
|
L
 48.9%
H
13.0
20.3
|
L
 -12.2%
H
12.1
35.3
|
L
 83.8%
H
5.7
71.7
|
L
 -35.3%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
23.6
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 1.4%
H
0.6
0.7
|
L
 16.4%
H
0.6
1.0
|
L
 34.0%
H
0.3
1.0
|
L
 -73.9%
H
0.3
2.8
|
L
 -38.3%
H
0.3
31.0
|
L
H
0.3
31.0
|
L
H
0.3
31.0
|
| Kamada Ltd |
|
492.7
|
8.5
|
L
 3.3%
H
8.3
8.6
|
L
 3.4%
H
8.1
8.6
|
L
 18.1%
H
6.9
8.6
|
L
 15.6%
H
6.9
8.6
|
L
 22.5%
H
6.5
9.4
|
L
 48.3%
H
4.1
9.4
|
L
 59.3%
H
3.7
9.4
|
L
 77.9%
H
3.7
13.3
|
| Kodiak Sciences Inc |
|
2,222.4
|
35.4
|
L
 -2.8%
H
35.2
36.6
|
L
 -9.6%
H
35.2
39.6
|
L
 -11.2%
H
35.2
46.9
|
L
 4.4%
H
29.2
46.9
|
L
 312.6%
H
8.3
47.8
|
L
 1373.3%
H
1.4
47.8
|
L
 -61.5%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
10,603.5
|
358.2
|
L
 -3.6%
H
353.7
372.0
|
L
 0.2%
H
345.1
373.3
|
L
 14.6%
H
313.8
373.3
|
L
 18.7%
H
297.0
382.5
|
L
 138.5%
H
136.7
382.5
|
L
 183.8%
H
94.0
382.5
|
L
 511.6%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
136.4
|
2.1
|
L
 1.9%
H
2.1
2.2
|
L
 0.5%
H
2
2.2
|
L
H
2.0
2.6
|
L
 0.9%
H
1.9
2.8
|
L
 -17.7%
H
0.4
3.4
|
L
 -98.6%
H
0.2
172.2
|
L
 -99.9%
H
0.2
2695
|
L
 -100.0%
H
0.2
131250
|
| Kura Oncology Inc |
|
1,178.7
|
13.3
|
L
 0.8%
H
12.9
13.3
|
L
 0.5%
H
12.4
13.4
|
L
 44.2%
H
9.1
13.9
|
L
 53%
H
8.4
13.9
|
L
 57.2%
H
7.4
13.9
|
L
 31.7%
H
5.4
24.2
|
L
 -30.3%
H
5.4
24.2
|
L
 124.2%
H
4
43
|
| Kymera Therapeutics Inc |
|
9,761.1
|
117.4
|
L
 0.1%
H
112.8
118.3
|
L
 -2.4%
H
112.8
123.5
|
L
 17.0%
H
100.5
127.9
|
L
 60.4%
H
72.7
130.1
|
L
 171.1%
H
40.7
130.1
|
L
 491.1%
H
9.6
130.1
|
L
 95.5%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
191.4
|
12.3
|
L
 1.2%
H
11.8
12.6
|
L
 -27.2%
H
11.8
15.5
|
L
 -0.8%
H
11.6
17.2
|
L
 12.4%
H
10.6
17.2
|
L
 53.3%
H
4.9
17.4
|
L
 -74.6%
H
2.9
79
|
L
 -97.6%
H
2.9
614
|
L
 -96.9%
H
2.9
792.5
|
| Longeveron Inc (Class A) |
|
21.7
|
6.8
|
L
 3.5%
H
6.5
6.9
|
L
 0.2%
H
6.5
7.3
|
L
 -7.0%
H
6.5
8.9
|
L
 -14.9%
H
5.8
8.9
|
L
 -16.5%
H
4.8
12.3
|
L
 -97.4%
H
4.8
429.8
|
L
 -98.2%
H
4.8
4500
|
L
H
4.8
4500
|
| Lixte biotech Holdings Inc |
|
73.7
|
4.0
|
L
 10.1%
H
3.5
4.1
|
L
 -8.8%
H
3.5
4.5
|
L
 -6.3%
H
3.1
4.6
|
L
 -39.9%
H
3.1
8.4
|
L
 -12.8%
H
2.4
8.4
|
L
 60.6%
H
0.6
8.4
|
L
 -83.4%
H
0.6
49.5
|
L
 -73.1%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
260.8
|
2.4
|
L
 6.6%
H
2.1
2.5
|
L
 28.0%
H
1.6
2.5
|
L
 278.1%
H
0.6
2.5
|
L
 105.1%
H
0.5
2.5
|
L
 734.5%
H
0.3
3.7
|
L
 9.0%
H
0.2
5
|
L
 -85.8%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
397.9
|
3.8
|
L
H
3.8
3.9
|
L
 -5.4%
H
3.8
4.1
|
L
 -3.8%
H
3.8
4.5
|
L
 19.7%
H
2.9
4.5
|
L
 -2.8%
H
2.7
6.4
|
L
H
1.6
13.7
|
L
 -74.1%
H
1.5
15
|
L
 -89.2%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
352.1
|
14.4
|
L
 0.4%
H
13.9
14.7
|
L
 -1.6%
H
13.9
15.1
|
L
 11.7%
H
12.9
17.2
|
L
 14.3%
H
11.5
17.2
|
L
 25.7%
H
11.2
45
|
L
 -69.3%
H
7.7
65.1
|
L
 -95.6%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
96.7
|
1.4
|
L
H
1.4
1.5
|
L
 -4%
H
1.4
1.5
|
L
 -18.6%
H
1.4
2.0
|
L
 -26.9%
H
1.4
2.0
|
L
 -59.3%
H
1.4
4.7
|
L
 -34.2%
H
0.8
4.7
|
L
 -80.4%
H
0.8
9.6
|
L
 -99.3%
H
0.8
234.9
|
| Seres Therapeutics Inc |
|
57.5
|
5.7
|
L
 1.4%
H
5.6
5.9
|
L
 15.6%
H
4.8
6.0
|
L
 13.7%
H
4.3
6.0
|
L
 -20.2%
H
4.3
8.3
|
L
 -69.1%
H
4.3
30.0
|
L
 57.6%
H
0.4
30.0
|
L
 -14.4%
H
0.4
30.0
|
L
 -43.5%
H
0.4
38.5
|
| Magenta Therapeutics Inc |
|
-
|
108.1
|
L
 0.2%
H
105.7
109.6
|
L
 -3.1%
H
102.4
111.3
|
L
 2.0%
H
102.4
117.9
|
L
 27.2%
H
68.9
117.9
|
L
 345.6%
H
23.7
117.9
|
L
 813.0%
H
10.9
117.9
|
L
 3.6%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,334.0
|
13.9
|
L
 -0.6%
H
13.6
14.0
|
L
 -1.8%
H
13.4
14.7
|
L
 16.9%
H
11.9
15.3
|
L
 47.9%
H
8.9
15.4
|
L
 89.5%
H
6.6
15.4
|
L
 118.1%
H
3.5
15.4
|
L
 12.4%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,494.0
|
28.2
|
L
 -0.2%
H
27.4
28.4
|
L
 8.5%
H
25.0
29.4
|
L
 9.4%
H
25.0
29.4
|
L
 12.6%
H
22.3
31.1
|
L
 -3.6%
H
22.3
47.7
|
L
 118.3%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
789.1
|
117.6
|
L
 -0.8%
H
116.2
119
|
L
 3.2%
H
106.7
121.0
|
L
 5.3%
H
104.5
124.8
|
L
 94.1%
H
57.7
124.8
|
L
 224.7%
H
35.0
124.8
|
L
 3596.9%
H
1.4
124.8
|
L
 371.2%
H
1.4
124.8
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
19.7
|
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 -19.2%
H
1.2
1.5
|
L
 -3.3%
H
1.1
1.6
|
L
 -18.6%
H
1.1
1.7
|
L
 35.6%
H
0.8
2.5
|
L
 -78.3%
H
0.8
6.8
|
L
 -94.0%
H
0.7
20.2
|
L
 -98.0%
H
0.7
135.5
|
| Moderna |
|
58,108.8
|
145.6
|
L
 -2.2%
H
141.5
154.7
|
L
 2.0%
H
133.3
156.4
|
L
 164.0%
H
53.7
176.7
|
L
 196.7%
H
45.4
176.7
|
L
 505.2%
H
22.3
176.7
|
L
 29.3%
H
22.3
176.7
|
L
 -65.1%
H
22.3
464.9
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,090.6
|
7.3
|
L
 -0.7%
H
7.2
7.4
|
L
 -12.5%
H
7.2
8.2
|
L
 14.0%
H
5.4
9.4
|
L
 51.2%
H
4.9
9.4
|
L
 210.2%
H
2.3
9.4
|
L
 -28.9%
H
1.7
11.6
|
L
 -87.5%
H
1.7
61.0
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
132.1
|
1.3
|
L
 1.6%
H
1.3
1.3
|
L
H
1.2
1.3
|
L
 19.6%
H
1.1
1.5
|
L
 6.7%
H
1.0
1.5
|
L
 -7.3%
H
0.6
1.9
|
L
 -65.4%
H
0.6
5.5
|
L
 -92.6%
H
0.6
17.3
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
133.7
|
1.6
|
L
 4.6%
H
1.5
1.6
|
L
 8.2%
H
1.4
1.7
|
L
 26.2%
H
1.2
1.7
|
L
 -35.4%
H
1.0
2.4
|
L
 -4.2%
H
0.3
4.9
|
L
 -98.7%
H
0.3
175.2
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,249.1
|
17.3
|
L
 1.1%
H
17.0
17.3
|
L
 -4.7%
H
16.5
18.1
|
L
 19.7%
H
14.6
18.3
|
L
 19.3%
H
13.1
19.4
|
L
 34.5%
H
13.1
21.5
|
L
 1062.4%
H
1.0
22
|
L
 171.9%
H
1.0
22
|
L
 253.5%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
166.6
|
4.4
|
L
H
4.4
4.4
|
L
 -6.5%
H
4.1
4.7
|
L
 5.6%
H
4.0
4.7
|
L
 7.9%
H
3.7
4.7
|
L
 16.9%
H
3.5
5.4
|
L
 -27.5%
H
3.3
12.7
|
L
 -78.7%
H
3.3
32.0
|
L
 -81.8%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
39.9
|
0.3
|
L
 -7.4%
H
0.3
0.3
|
L
 -7.4%
H
0.3
0.3
|
L
 -21.9%
H
0.3
0.4
|
L
 -24.2%
H
0.3
0.4
|
L
 -85.6%
H
0.2
2.4
|
L
 -82.6%
H
0.2
5.0
|
L
 -90.9%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
114.5
|
0.9
|
L
 -2.2%
H
0.9
1.0
|
L
H
0.9
1.0
|
L
 -10.9%
H
0.8
1.1
|
L
 -65.1%
H
0.8
2.8
|
L
 40.6%
H
0.6
4.3
|
L
 -73.6%
H
0.6
4.3
|
L
 -88.3%
H
0.6
8.6
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
15,820.7
|
155.6
|
L
 -1.7%
H
154.8
159.8
|
L
 -0.2%
H
151.8
160.4
|
L
 -6.4%
H
148.8
169.0
|
L
 -5.7%
H
148.8
186.1
|
L
 14.4%
H
122.1
186.1
|
L
 40.7%
H
84.2
186.1
|
L
 62.3%
H
71.9
186.1
|
L
 214.8%
H
37.3
186.1
|
| Nkarta Inc |
|
209.1
|
2.9
|
L
 4.7%
H
2.8
2.9
|
L
 6.2%
H
2.6
2.9
|
L
 35.8%
H
2.1
2.9
|
L
 7.4%
H
2.0
3.7
|
L
 39.1%
H
1.7
3.7
|
L
 65.0%
H
1.3
16.2
|
L
 -89.9%
H
1.3
31.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
38.6
|
L
 2.6%
H
36.6
39.4
|
L
 2.0%
H
35.3
39.8
|
L
 17.4%
H
30.6
42.0
|
L
 47.2%
H
24.9
43.7
|
L
 94.3%
H
15.9
43.7
|
L
 157.0%
H
12.7
43.7
|
L
 -75.1%
H
7.5
169.6
|
L
 -84.1%
H
7.5
399.4
|
| MetaVia Inc |
|
11.5
|
1.8
|
L
 -4.9%
H
1.7
1.9
|
L
 5.4%
H
1.7
1.9
|
L
 18.2%
H
1.4
1.9
|
L
 -34.7%
H
1.4
2.8
|
L
 -76.3%
H
1.0
19.0
|
L
 -95.6%
H
1.0
74.3
|
L
 -100.0%
H
1.0
11352
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,712.9
|
26.1
|
L
 3.2%
H
25.0
26.2
|
L
 -2.8%
H
25.0
26.9
|
L
 12.6%
H
23.2
28.2
|
L
 68.9%
H
14.2
28.2
|
L
 176.3%
H
8.2
28.2
|
L
 202.2%
H
4.2
29.6
|
L
 -21.1%
H
4.2
37.4
|
L
H
4.2
52.4
|
| Intellia Therapeutics Inc |
|
1,785.2
|
12.7
|
L
 0.5%
H
12.5
13.0
|
L
 -2.8%
H
12.3
13.5
|
L
 18.3%
H
10.6
13.7
|
L
 -2.2%
H
10.2
18.5
|
L
 8.8%
H
8.0
28.3
|
L
 -66.2%
H
5.9
38.7
|
L
 -92.8%
H
5.9
180.6
|
L
 -35.7%
H
5.9
202.7
|
| Natera Inc |
|
47,305.2
|
328.2
|
L
 0.2%
H
323.4
329.1
|
L
 -3.1%
H
316
339.3
|
L
 21.4%
H
263.6
343.2
|
L
 54.9%
H
208.8
343.2
|
L
 95.9%
H
157.4
343.2
|
L
 424.9%
H
36.9
343.2
|
L
 165.2%
H
26.1
343.2
|
L
 3114.3%
H
7.4
343.2
|
| Novavax Inc |
|
1,685.7
|
10.2
|
L
 -1.2%
H
10.0
10.8
|
L
 12.9%
H
8.9
10.8
|
L
 37.9%
H
7.5
10.8
|
L
 0.2%
H
7.2
10.8
|
L
 38.1%
H
6.2
12.0
|
L
 24.5%
H
3.5
23.9
|
L
 -95.9%
H
3.5
277.8
|
L
 -92.5%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
5.8
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 -4.8%
H
1.3
1.9
|
L
 3.7%
H
1.3
1.9
|
L
 -31.0%
H
1.2
2.2
|
L
 -54.0%
H
1.2
7.2
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Insight Molecular Diagnostics Inc |
|
135.2
|
4.1
|
L
 0.2%
H
4.0
4.2
|
L
 -3.7%
H
3.7
4.5
|
L
 -17.9%
H
3.5
5.3
|
L
 -31.5%
H
3.5
6.9
|
L
 61.3%
H
2.4
8.5
|
L
 19.0%
H
1.9
8.5
|
L
 -95.1%
H
1.9
85.9
|
L
 -94.1%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
82.4
|
1.6
|
L
 1.3%
H
1.5
1.6
|
L
 1.3%
H
1.5
1.7
|
L
 -6.0%
H
1.5
1.7
|
L
 -5.4%
H
1.3
1.9
|
L
 -30.8%
H
1.3
3.2
|
L
 -21.1%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
107.1
|
0.8
|
L
 -2.3%
H
0.8
0.9
|
L
 -1.2%
H
0.8
0.9
|
L
 7.7%
H
0.8
0.9
|
L
 -4.6%
H
0.7
1.1
|
L
 -27.6%
H
0.7
1.5
|
L
 -64.7%
H
0.3
2.4
|
L
 -62.7%
H
0.3
3.4
|
L
 -70.5%
H
0.3
8.5
|
| Traws Pharma Inc |
|
8.5
|
0.6
|
L
 1.9%
H
0.5
0.6
|
L
 -5.2%
H
0.5
0.6
|
L
 17.0%
H
0.5
0.6
|
L
 -62.1%
H
0.4
1.5
|
L
 -65.8%
H
0.4
3.3
|
L
 -97.2%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
21825
|
| VivoSim Labs Inc |
|
3.7
|
0.3
|
L
H
0.3
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -17.7%
H
0.3
0.6
|
L
 -77.8%
H
0.3
1.6
|
L
 -88.9%
H
0.3
5.3
|
L
 -97.9%
H
0.3
24.6
|
L
 -99.7%
H
0.3
95.5
|
L
 -100.0%
H
0.3
1027.2
|
| Passage Bio Inc |
|
15.0
|
4.7
|
L
 -2.1%
H
4.6
4.9
|
L
 7.4%
H
4.3
4.9
|
L
 3.6%
H
4.3
5.0
|
L
 -22.1%
H
3.3
6.3
|
L
 -34.7%
H
3.3
20
|
L
 -70.0%
H
3.3
35.8
|
L
 -98.0%
H
3.3
242
|
L
H
3.3
764.6
|
| Vaxcyte Inc |
|
9,100.9
|
61.2
|
L
 0.0%
H
59.6
61.8
|
L
H
58.5
62.9
|
L
 14.3%
H
53.6
64.0
|
L
 30.3%
H
45.3
64.0
|
L
 90.5%
H
30.8
65
|
L
 15.2%
H
27.7
121.1
|
L
 138.3%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
215.4
|
3.1
|
L
 -2.2%
H
3.1
3.2
|
L
 1.3%
H
2.9
3.3
|
L
 65.4%
H
1.8
3.6
|
L
 119.0%
H
1.3
3.6
|
L
 161.3%
H
1.2
7.8
|
L
 -51.9%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,542.1
|
7.1
|
L
 -0.6%
H
7.1
7.3
|
L
 -1.3%
H
6.6
7.3
|
L
 7.4%
H
6.1
7.7
|
L
 86.4%
H
3.5
7.7
|
L
 49.5%
H
3.0
7.7
|
L
 292.3%
H
0.7
7.7
|
L
 15.6%
H
0.7
7.7
|
L
 -72.0%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.5
|
1.1
|
L
 -2.7%
H
1.1
1.1
|
L
 -3.6%
H
1.1
1.2
|
L
 4.9%
H
1.0
1.2
|
L
 -2.7%
H
0.8
1.2
|
L
 -48.1%
H
0.8
4.2
|
L
 -94.4%
H
0.6
29.1
|
L
 -99.5%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,474.7
|
35.3
|
L
 -1.2%
H
35.2
36.4
|
L
 -4.7%
H
33.8
37.4
|
L
 9.3%
H
32.6
38.1
|
L
 17.0%
H
29.6
38.1
|
L
 60.9%
H
20.7
38.1
|
L
 65.3%
H
11.5
38.1
|
L
 85.4%
H
1.8
38.1
|
L
H
1.8
42.9
|
| Pliant Therapeutics Inc |
|
71.8
|
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 11.5%
H
1.0
1.2
|
L
 -1.7%
H
1.0
1.2
|
L
 -32.2%
H
1.0
2.0
|
L
 -93.1%
H
1.0
19.6
|
L
 -94.0%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
16.3
|
1.4
|
L
 -0.7%
H
1.3
1.5
|
L
 -11.1%
H
1.3
1.6
|
L
 -13.9%
H
1.3
1.9
|
L
 -42.4%
H
1.3
2.6
|
L
 -73.6%
H
1.3
5.3
|
L
 -73.4%
H
0.7
8.5
|
L
 -94.6%
H
0.7
25.6
|
L
 -99.0%
H
0.7
169.6
|
| ProMIS Neurosciences Inc |
|
113.0
|
12.6
|
L
 -2.3%
H
12.5
13.5
|
L
 -9.9%
H
12.5
14.6
|
L
 -10.9%
H
12.5
16.0
|
L
 30.6%
H
9.1
17.3
|
L
 10.3%
H
6.3
27.4
|
L
 -75.4%
H
6.3
77.5
|
L
 -94.7%
H
6.3
245.4
|
L
 -93.2%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
69.0
|
1.3
|
L
 4.0%
H
1.2
1.4
|
L
 4.0%
H
1.1
1.4
|
L
 15.2%
H
1.1
1.4
|
L
 11.2%
H
1.0
1.5
|
L
 -16.8%
H
1.0
1.9
|
L
 -82.4%
H
0.8
7.4
|
L
 -95.4%
H
0.8
31.3
|
L
H
0.8
63.2
|
| Prelude Therapeutics Inc |
|
435.7
|
5.5
|
L
 4%
H
5.2
5.5
|
L
 -13.9%
H
5.1
6.4
|
L
 24.4%
H
4.4
6.8
|
L
 49.2%
H
3.6
6.8
|
L
 347.5%
H
1.0
6.8
|
L
 49.2%
H
0.6
6.8
|
L
 -85.4%
H
0.6
38.7
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
671.1
|
3.7
|
L
 -0.3%
H
3.7
3.9
|
L
 1.7%
H
3.5
3.9
|
L
 31.7%
H
2.8
3.9
|
L
 17.8%
H
2.7
4.8
|
L
 10.8%
H
2.7
6.9
|
L
 -71.0%
H
1.1
13.3
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
419.9
|
2.0
|
L
 4.7%
H
1.9
2.1
|
L
 10.4%
H
1.8
2.1
|
L
 28.9%
H
1.3
2.1
|
L
 16.2%
H
1.3
2.2
|
L
 -14.8%
H
1.3
3.5
|
L
 -76.7%
H
0.5
8.8
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
504.1
|
9.8
|
L
 2.3%
H
9.5
9.9
|
L
 8.0%
H
9.0
9.9
|
L
 17.9%
H
8.0
9.9
|
L
 10.1%
H
7.7
10.2
|
L
 17.0%
H
7.7
11.8
|
L
 -82.2%
H
4.3
56.0
|
L
 -86.2%
H
4.3
79.8
|
L
 -81.2%
H
4.3
79.8
|
| Quince Therapeutics Inc |
|
31.9
|
31.3
|
L
 2.5%
H
30
33.4
|
L
 -3.6%
H
30
35.3
|
L
 25.5%
H
24.8
35.4
|
L
 2940.8%
H
0.9
35.4
|
L
 94.5%
H
0.8
45.5
|
L
 140.9%
H
0.8
45.5
|
L
 -96.6%
H
0.8
1010
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,086.8
|
44.5
|
L
 -0.8%
H
43.9
45.2
|
L
 -10.2%
H
43.9
51.0
|
L
 1%
H
42.6
51.7
|
L
 48.9%
H
25.7
51.7
|
L
 156.0%
H
8.7
71.5
|
L
 410.3%
H
3.7
71.5
|
L
 43.0%
H
3.7
71.5
|
L
 477.9%
H
3.7
82.5
|
| Rani Therapeutics Holdings Inc |
|
99.3
|
0.9
|
L
 1.2%
H
0.9
0.9
|
L
 1.2%
H
0.8
0.9
|
L
 7.5%
H
0.8
0.9
|
L
 -2.3%
H
0.6
0.9
|
L
 79.2%
H
0.4
3.9
|
L
 -77.4%
H
0.4
8.8
|
L
 -95.7%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
423.7
|
3.9
|
L
 1.9%
H
3.7
3.9
|
L
 6.6%
H
3.5
4.0
|
L
 13.2%
H
3.3
4.0
|
L
 32.2%
H
2.5
4.3
|
L
 16.3%
H
2.5
5.5
|
L
 -75.9%
H
2.2
32.5
|
L
 -89.3%
H
2.2
36.9
|
L
 -86.5%
H
2.2
67.5
|
| Replimune Grp Inc |
|
1,417.1
|
15.0
|
L
 -1.6%
H
14.8
15.3
|
L
 -3.6%
H
14.8
16.3
|
L
 26.3%
H
11.4
16.3
|
L
 50.7%
H
4.8
16.3
|
L
 154.9%
H
1.5
16.3
|
L
 -23.7%
H
1.5
20.4
|
L
 -54.3%
H
1.5
35.9
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.0
|
1.0
|
L
H
1.0
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 -1.0%
H
0.9
1.2
|
L
 -2.9%
H
0.9
1.2
|
L
 -90.8%
H
0.9
11.6
|
L
 -100.0%
H
0.9
5417.6
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
4,172.5
|
19.0
|
L
 0.2%
H
18.7
19.3
|
L
 -2.0%
H
18.0
19.3
|
L
 1.4%
H
18.0
21.3
|
L
 24.4%
H
12.9
21.3
|
L
 363.3%
H
3.9
21.3
|
L
 72.6%
H
1.8
21.3
|
L
 -39.6%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Rallybio Corp |
|
89.9
|
16.9
|
L
 0.2%
H
16.8
17.0
|
L
 1.0%
H
16.5
17.3
|
L
 6.1%
H
15.9
17.4
|
L
 5.3%
H
15.6
17.4
|
L
 266.2%
H
3.7
17.6
|
L
 -60.9%
H
1.8
47.7
|
L
 -85%
H
1.8
168
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
2.2
|
2.1
|
L
 -4.6%
H
2.1
2.2
|
L
 -9.7%
H
1.8
2.4
|
L
 -51.2%
H
1.8
4.7
|
L
 -59.1%
H
1.8
10.7
|
L
 -80.3%
H
1.8
21.0
|
L
 -100.0%
H
1.8
118272
|
L
 -100.0%
H
1.8
3901941.1
|
L
H
1.8
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,946.7
|
3.6
|
L
 5.5%
H
3.4
3.7
|
L
 5.5%
H
3.3
3.7
|
L
 14.2%
H
2.9
3.7
|
L
 4.6%
H
2.8
4.1
|
L
 -21.6%
H
2.8
7.2
|
L
 -60.2%
H
2.8
15.7
|
L
 -86.6%
H
2.8
29.4
|
L
H
2.8
42.8
|
| SAB Biotherapeutics Inc |
|
338.5
|
3.7
|
L
H
3.7
3.8
|
L
 -5.3%
H
3.6
4.0
|
L
 -1.9%
H
3.6
4.0
|
L
 10.7%
H
3.3
4.2
|
L
 60.3%
H
1.9
5.2
|
L
 409.6%
H
0.4
6.6
|
L
 -62.8%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
1,152.5
|
3.9
|
L
 -1.8%
H
3.8
3.9
|
L
 -5.9%
H
3.7
4.1
|
L
 21.1%
H
3.2
4.2
|
L
 23.4%
H
2.6
4.2
|
L
 28.8%
H
2.6
6.6
|
L
 -27.9%
H
1.3
12
|
L
 -84.4%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
39.6
|
0.8
|
L
 -1.2%
H
0.8
0.9
|
L
 -10.9%
H
0.8
0.9
|
L
 -20.4%
H
0.8
1.1
|
L
 -39.7%
H
0.8
1.5
|
L
 -62.9%
H
0.8
5.0
|
L
 -96.1%
H
0.8
42.2
|
L
 -98.4%
H
0.8
100
|
L
 -94.8%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
108.0
|
2.0
|
L
 0.5%
H
1.9
2.0
|
L
 -3.0%
H
1.9
2.0
|
L
 -13.0%
H
1.9
2.2
|
L
 4.8%
H
1.6
2.3
|
L
 -3.5%
H
1.6
2.4
|
L
 -28.3%
H
1.5
2.7
|
L
 -95.5%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,435.5
|
9.3
|
L
 1.6%
H
8.9
9.3
|
L
 -7.0%
H
8.8
10.6
|
L
 17.8%
H
7.8
10.9
|
L
 48.1%
H
5.8
11
|
L
 -9.6%
H
5.6
11
|
L
 -9.6%
H
5.6
15.6
|
L
 -9.6%
H
5.6
15.6
|
L
 -9.6%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
1,099.1
|
10.3
|
L
 -1.6%
H
10.2
10.5
|
L
 1.2%
H
9.4
10.5
|
L
 27.8%
H
8.2
10.5
|
L
 49.6%
H
6.3
11.5
|
L
 78.3%
H
3.8
11.5
|
L
 183.1%
H
1.8
15.1
|
L
 -75.6%
H
1.8
51.3
|
L
H
1.8
822.6
|
| Decoy Therapeutics Inc |
|
1.8
|
2.7
|
L
 -6.6%
H
2.7
2.9
|
L
 -9.4%
H
2.7
3.3
|
L
 -38.0%
H
2.7
4.5
|
L
 -66.3%
H
2.7
13.5
|
L
 -95.3%
H
2.7
70.8
|
L
 -99.8%
H
2.7
1368
|
L
 -100.0%
H
2.7
43200
|
L
 -100.0%
H
2.7
10863000
|
| Summit Therapeutics Inc |
|
14,040.4
|
17.6
|
L
 2.7%
H
16.8
17.6
|
L
 22.8%
H
13.4
17.6
|
L
 35.0%
H
12.1
17.6
|
L
 16.8%
H
12.1
17.6
|
L
 -25.2%
H
12.1
29.2
|
L
 979.8%
H
1.5
36.9
|
L
 139.1%
H
0.7
36.9
|
L
 164.7%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,835.9
|
20.6
|
L
 -0.6%
H
20.5
21
|
L
 2.0%
H
19
21
|
L
 6.9%
H
17.2
21
|
L
 12.1%
H
16.7
25.2
|
L
 27.5%
H
13.0
25.6
|
L
 5.2%
H
8.6
25.6
|
L
 15.2%
H
8.6
29.9
|
L
 46.8%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
1,034.9
|
40.1
|
L
 2.7%
H
38.4
41.2
|
L
 18.7%
H
31.8
41.2
|
L
 46.5%
H
23.1
41.2
|
L
 152.8%
H
10.8
41.2
|
L
 361.4%
H
7.5
41.2
|
L
 94.4%
H
5
41.2
|
L
 -83.2%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
10.3
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 -13.2%
H
0.3
0.4
|
L
 -10.8%
H
0.3
0.5
|
L
 -66.3%
H
0.3
1.2
|
L
 -77.1%
H
0.3
2.9
|
L
 -95.1%
H
0.3
16.9
|
L
 -66.7%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
166.5
|
57.9
|
L
 0.4%
H
56.6
58.2
|
L
 -8.5%
H
55.3
63.0
|
L
 34.3%
H
43.7
64.5
|
L
 18.1%
H
40.3
64.5
|
L
 559.0%
H
7.3
240
|
L
 -65.4%
H
4.3
446.3
|
L
 -90.2%
H
4.3
619.5
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
70.5
|
1.2
|
L
 -0.8%
H
1.2
1.2
|
L
H
1.2
1.2
|
L
 5.2%
H
1.2
1.3
|
L
 -56.8%
H
1.1
3.1
|
L
 -41.8%
H
1.1
3.1
|
L
 -20.4%
H
0.5
3.2
|
L
 -93.2%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,738.4
|
55.3
|
L
 -1.1%
H
55
56.0
|
L
 -6.6%
H
55
59.3
|
L
 20.7%
H
46.3
61.8
|
L
 24.0%
H
43.2
61.8
|
L
 60.9%
H
27.1
61.8
|
L
 779.7%
H
5.9
61.8
|
L
 52.0%
H
4.3
61.8
|
L
H
4.3
70
|
| Surrozen Inc |
|
267.5
|
22.8
|
L
 1.0%
H
21.5
22.9
|
L
 -5.2%
H
21.5
23.8
|
L
 4.5%
H
20.7
27.3
|
L
 -7.4%
H
18.1
27.3
|
L
 81.5%
H
11.3
35
|
L
 4038.2%
H
0.3
35
|
L
 214.4%
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,923.5
|
29.8
|
L
 -0.6%
H
29.1
30.0
|
L
 -8.5%
H
29.1
32.6
|
L
 0.9%
H
28.8
33.9
|
L
 1.2%
H
27.2
33.9
|
L
 50.8%
H
18.8
40.2
|
L
 438.1%
H
3.4
40.2
|
L
 17.6%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
681.5
|
6.8
|
L
 -2.4%
H
6.7
6.9
|
L
 -11.2%
H
6.7
7.6
|
L
 -6.9%
H
6.7
8.2
|
L
 43.0%
H
3.3
8.2
|
L
 430.5%
H
1.2
8.3
|
L
 201.8%
H
0.7
11.8
|
L
 -68.1%
H
0.7
22.6
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
3.2
|
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 -13.2%
H
0.9
1.1
|
L
 -20.7%
H
0.9
1.3
|
L
 -36.6%
H
0.9
1.9
|
L
 -84.3%
H
0.9
8.6
|
L
 -99.7%
H
0.9
367.2
|
L
H
0.9
2076
|
L
H
0.9
2076
|
| Alaunos Therapeutics Inc |
|
4.1
|
1.6
|
L
 -1.2%
H
1.6
1.7
|
L
 -1.8%
H
1.6
1.7
|
L
 -14.2%
H
1.6
2.1
|
L
 -37.8%
H
1.6
2.6
|
L
 -27.2%
H
1.6
4.6
|
L
 1064.3%
H
0.0
6.2
|
L
 -1.2%
H
0.0
6.2
|
L
 -67.0%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
26.4
|
0.4
|
L
 5.4%
H
0.4
0.4
|
L
 -48%
H
0.4
0.8
|
L
 -45.8%
H
0.4
0.8
|
L
 -59.8%
H
0.4
1.3
|
L
 -79.1%
H
0.4
2.6
|
L
 -84.1%
H
0.4
9.7
|
L
 -95.4%
H
0.4
9.7
|
L
H
0.4
14.7
|
| Bio-Techne |
|
11,358.3
|
72.4
|
L
 0.0%
H
72.4
72.5
|
L
 -0.1%
H
72.1
72.6
|
L
 0.4%
H
71.9
72.6
|
L
 42.4%
H
51.3
72.6
|
L
 35.8%
H
43.2
72.6
|
L
 -8.0%
H
43.2
85.6
|
L
 -43.5%
H
43.2
136.0
|
L
 171.1%
H
23.9
136.0
|
| Instil Bio Inc |
|
51.4
|
7.6
|
L
 -1.0%
H
7.6
7.6
|
L
 -3.6%
H
7.5
7.8
|
L
 5.0%
H
7.0
7.9
|
L
 -7.9%
H
7.0
8.3
|
L
 -73.9%
H
5.7
33.8
|
L
 1547.8%
H
0.3
92
|
L
 -64.7%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
3,797.1
|
22.5
|
L
 -1.1%
H
22.3
22.9
|
L
 -10.9%
H
21.6
25.1
|
L
 -17.2%
H
21.6
30.3
|
L
 4.9%
H
19.4
34.4
|
L
 236.1%
H
6.3
34.4
|
L
 214.5%
H
1.0
34.4
|
L
 74.2%
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
277.6
|
7.1
|
L
 -0.6%
H
7
7.2
|
L
 -1.9%
H
6.8
7.4
|
L
 -1.8%
H
6.7
8.0
|
L
 8.4%
H
5.7
8.1
|
L
 34.0%
H
5.0
16.5
|
L
 -53.7%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,459.1
|
17.3
|
L
 1.2%
H
16.8
17.3
|
L
 -3.9%
H
16.1
18.1
|
L
 -3.6%
H
16.1
19.3
|
L
 28.3%
H
13.2
20.2
|
L
 141.4%
H
6.9
20.2
|
L
 650.4%
H
1.0
20.2
|
L
 978.8%
H
0.5
20.2
|
L
H
0.5
20.2
|
| Taysha Gene Therapies Inc |
|
1,824.7
|
5.6
|
L
 0.5%
H
5.4
5.6
|
L
 -6.0%
H
5.4
6.0
|
L
 -3.1%
H
5.4
6.8
|
L
 0.9%
H
5.3
7.1
|
L
 93.1%
H
2.7
7.3
|
L
 54.3%
H
1.1
7.3
|
L
 -71.4%
H
0.5
21.9
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
8,210.6
|
124.7
|
L
 -3.1%
H
123.8
128.1
|
L
 -18.5%
H
123.8
153.1
|
L
 23.4%
H
98.9
155.4
|
L
 72.4%
H
66.4
155.4
|
L
 379.7%
H
23.3
155.4
|
L
 429.4%
H
14.4
155.4
|
L
 8.7%
H
11.5
155.4
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
8,162.7
|
62.7
|
L
 -0.9%
H
61.0
63.5
|
L
 -3.4%
H
58.7
65
|
L
 33.3%
H
44.4
66.9
|
L
 94.8%
H
28.0
66.9
|
L
 369.6%
H
11.2
66.9
|
L
 15.9%
H
6.8
66.9
|
L
 -66.2%
H
6.8
191.2
|
L
H
6.8
209.0
|
| Tyra Biosciences Inc |
|
1,709.7
|
28.7
|
L
 15.3%
H
24.5
29.6
|
L
 9.6%
H
24.2
29.6
|
L
 -10.6%
H
24.2
33.0
|
L
 -0.1%
H
24.2
33.7
|
L
 132.6%
H
11.7
40.7
|
L
 91%
H
6.4
40.7
|
L
H
4.9
40.7
|
L
H
4.9
40.7
|
| Unicycive Therapeutics Inc |
|
143.7
|
5.2
|
L
 -2.6%
H
5.1
5.2
|
L
 -6.2%
H
5.0
5.5
|
L
 2.0%
H
4.9
5.9
|
L
 -28.3%
H
3.9
8.6
|
L
 20.3%
H
3.7
8.7
|
L
 -35.5%
H
2.0
18.2
|
L
 -81.1%
H
2.0
31.9
|
L
H
2.0
87.3
|
| TradeUP Acq Corp |
|
-
|
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -9.7%
H
0.6
0.8
|
L
 -7.1%
H
0.6
0.9
|
L
 -37.5%
H
0.6
1.2
|
L
 -39.8%
H
0.6
3.2
|
L
 -96.9%
H
0.6
23.9
|
L
H
0.6
33
|
L
H
0.6
33
|
| UroGen Pharma Ltd |
|
2,155.1
|
44.1
|
L
 -1.8%
H
43.5
45.1
|
L
 -3.1%
H
42
45.9
|
L
 14.3%
H
38.8
50.8
|
L
 65.8%
H
26.4
50.8
|
L
 127.6%
H
15.9
50.8
|
L
 143.1%
H
3.4
50.8
|
L
 146.0%
H
3.4
50.8
|
L
H
3.4
69.6
|
| United Therapeutics Corp |
|
20,913.9
|
487.6
|
L
 -0.5%
H
484.3
494.1
|
L
 -7.6%
H
477.0
530.5
|
L
 -5.6%
H
477.0
541.0
|
L
 -11.3%
H
477.0
563.7
|
L
 24.6%
H
375.6
609.4
|
L
 113.8%
H
208.6
609.4
|
L
 131.3%
H
158.4
609.4
|
L
 296.7%
H
74.3
609.4
|
| Vera Therapeutics Inc (Class A) |
|
2,586.4
|
35.9
|
L
 2.6%
H
34.7
36.4
|
L
 3.7%
H
33.2
36.4
|
L
 11.4%
H
28.9
37.0
|
L
 14.8%
H
28.9
44.9
|
L
 56.3%
H
21.7
56.1
|
L
 93.6%
H
9.2
56.1
|
L
 39.1%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,925.7
|
11.4
|
L
 -0.6%
H
11.2
11.6
|
L
 0.6%
H
10.7
11.9
|
L
 27.9%
H
8.6
11.9
|
L
 29.8%
H
8.2
11.9
|
L
 106.5%
H
4.8
11.9
|
L
 -9.0%
H
4.2
14.5
|
L
 -76.8%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
1,482.0
|
25.1
|
L
 3.3%
H
24
25.2
|
L
 6.5%
H
22.1
25.2
|
L
 17%
H
21.5
25.2
|
L
 86.4%
H
12.6
25.2
|
L
 1152.5%
H
1.5
50.0
|
L
 838.2%
H
0.1
50.0
|
L
 61.3%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
742.6
|
8.2
|
L
 2.8%
H
7.7
8.2
|
L
 11.1%
H
7
8.2
|
L
 44.1%
H
5.6
8.2
|
L
 126.5%
H
3.4
8.2
|
L
 -13.7%
H
3.4
11.2
|
L
 -16.8%
H
2.1
14.2
|
L
 -75.1%
H
2.1
43.0
|
L
 -48.6%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
10.7
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -7.7%
H
0.2
0.3
|
L
H
0.2
0.3
|
L
 -57.1%
H
0.2
0.8
|
L
 -93.5%
H
0.2
5.1
|
L
 -95.9%
H
0.2
7.4
|
L
 -99.7%
H
0.2
97.8
|
L
 -99.8%
H
0.2
140.7
|
| Voyager Therapeutics Inc |
|
216.3
|
3.5
|
L
 3.9%
H
3.3
3.5
|
L
 1.5%
H
3.3
3.6
|
L
 17%
H
3.0
3.6
|
L
 -2.5%
H
2.9
3.9
|
L
 -4.6%
H
2.9
5.6
|
L
 -65.2%
H
2.6
11.7
|
L
 5.4%
H
2.5
14.3
|
L
 -70.0%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
653.3
|
6.9
|
L
 -2.4%
H
6.9
7
|
L
 5.0%
H
6.3
7.2
|
L
 35.9%
H
5.1
7.3
|
L
 23.5%
H
4.8
7.3
|
L
 -21.4%
H
4.8
12.2
|
L
 -50.6%
H
3.6
14.9
|
L
 -85.6%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
957.7
|
4.9
|
L
 3.4%
H
4.7
4.9
|
L
 -5.8%
H
4.6
5.2
|
L
 -15.3%
H
4.6
6.4
|
L
 -15.6%
H
4.6
6.5
|
L
 -39.3%
H
4.6
21.7
|
L
 7.0%
H
3.5
21.7
|
L
 -22.0%
H
1.2
21.7
|
L
 -80.6%
H
1.2
56
|
| XBiotech Inc |
|
67.1
|
2.2
|
L
H
2.2
2.3
|
L
 -4.4%
H
2.2
2.3
|
L
 -1.8%
H
2.2
2.5
|
L
 -8.0%
H
2.2
2.5
|
L
 -26.2%
H
2.1
3.4
|
L
 -53.8%
H
2.1
10.0
|
L
 -86.2%
H
2.1
16.5
|
L
 -83.4%
H
2.1
26.4
|
| Exicure Inc |
|
8.2
|
1.3
|
L
 1.6%
H
1.2
1.3
|
L
 -11.4%
H
1.2
1.4
|
L
 -20.9%
H
1.1
1.6
|
L
 -60.4%
H
1.1
3.2
|
L
 -75.6%
H
1.1
9.5
|
L
 -72.5%
H
0.3
36
|
L
 -99.4%
H
0.3
213
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,555.2
|
8.5
|
L
 -0.7%
H
8.4
8.6
|
L
 -0.8%
H
8.3
8.8
|
L
 4.9%
H
7.1
9.0
|
L
 44.8%
H
5.9
9.0
|
L
 8.8%
H
5.3
10.1
|
L
 259.9%
H
1.5
10.1
|
L
 213.6%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
400.6
|
4.0
|
L
H
4
4.1
|
L
 -4.5%
H
4.0
4.2
|
L
 -1.2%
H
3.9
4.8
|
L
 1.8%
H
3.6
4.8
|
L
 29.5%
H
2.8
4.8
|
L
 210.8%
H
0.2
6.6
|
L
 -22.2%
H
0.2
6.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,978.5
|
26.6
|
L
 0.0%
H
25.4
26.8
|
L
 -7.9%
H
25.4
29.0
|
L
 37.2%
H
19.1
30.6
|
L
 133.0%
H
11.2
30.6
|
L
 219.5%
H
8.1
30.6
|
L
 18.6%
H
6.9
30.6
|
L
 -21.3%
H
6.9
43.6
|
L
 30.8%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.7
|
2.5
|
L
 7.5%
H
2.3
2.5
|
L
 -19.4%
H
2.3
3.8
|
L
 -41.7%
H
2.3
4.6
|
L
 400%
H
0.3
7.3
|
L
 -90.7%
H
0.3
32.3
|
L
 -100.0%
H
0.3
1259089.9
|
L
 -100.0%
H
0.3
39346560
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
377.7
|
4.0
|
L
 -2.9%
H
3.9
4.2
|
L
 2.8%
H
3.6
4.2
|
L
 -14.2%
H
3.5
5.2
|
L
 7.3%
H
3.4
5.6
|
L
 133.3%
H
1.2
7.0
|
L
 -85.3%
H
1.0
27.0
|
L
 -94.0%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
597.0
|
6.2
|
L
 6.0%
H
5.6
6.3
|
L
 6.5%
H
5.4
6.3
|
L
 12.9%
H
5.4
7.1
|
L
 61.4%
H
3.3
7.1
|
L
 206.9%
H
1.9
7.4
|
L
 -10.7%
H
1.0
7.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,944.7
|
26.2
|
L
 -2.9%
H
25.5
26.5
|
L
 -2.2%
H
24.8
27.5
|
L
 44.3%
H
18.2
27.5
|
L
 52.8%
H
16.3
27.5
|
L
 -16.2%
H
16.0
34.7
|
L
 0.5%
H
13.5
44.3
|
L
 -82.0%
H
13.5
152.8
|
L
H
13.5
193.5
|
| Intensity Therapeutics Inc |
|
13.4
|
4.1
|
L
 2.5%
H
4.0
4.1
|
L
 -4.0%
H
4.0
4.6
|
L
 -3.8%
H
3.9
5.2
|
L
 2.0%
H
3.5
5.2
|
L
 -39.3%
H
3.5
43.5
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
L
 -95.9%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
10.8
|
2.4
|
L
 1.7%
H
2.3
2.4
|
L
 1.7%
H
2.2
2.5
|
L
H
2.1
3.2
|
L
 -16.7%
H
1.9
5.0
|
L
 -86.6%
H
1.2
17.8
|
L
 -99.1%
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
36.3
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 -6.8%
H
0.8
1.0
|
L
 -5.8%
H
0.8
1.1
|
L
 -17.2%
H
0.8
1.1
|
L
 -58.8%
H
0.5
2.1
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Dianthus Therapeutics Inc |
|
6,046.5
|
108.1
|
L
 0.2%
H
105.7
109.6
|
L
 -3.1%
H
102.4
111.3
|
L
 2.0%
H
102.4
117.9
|
L
 27.2%
H
68.9
117.9
|
L
 345.6%
H
23.7
117.9
|
L
 14123.7%
H
6.6
117.9
|
L
 14123.7%
H
6.6
117.9
|
L
 14123.7%
H
6.6
117.9
|
| Incannex Healthcare Ltd (ADR) |
|
38.8
|
3.2
|
L
 -0.3%
H
3.2
3.3
|
L
 -12.2%
H
3.1
3.8
|
L
 10.6%
H
2.9
3.9
|
L
 5.9%
H
2.8
4.2
|
L
 -82.7%
H
2.5
20.3
|
L
 -98.0%
H
2.4
160.2
|
L
 -98.0%
H
2.4
160.2
|
L
 -98.0%
H
2.4
160.2
|
| Canton Strategic Holdings Inc |
|
181.7
|
2.3
|
L
 1.3%
H
2.2
2.3
|
L
 -3.0%
H
2.0
2.4
|
L
 14%
H
1.8
2.4
|
L
 -6.9%
H
1.8
3.8
|
L
 -52.2%
H
1.8
6.9
|
L
 -97.5%
H
0.3
142.5
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Estrella Biopharma Inc |
|
28.3
|
0.7
|
L
 1.6%
H
0.6
0.7
|
L
 -9.7%
H
0.6
0.8
|
L
 -7.1%
H
0.6
0.9
|
L
 -37.5%
H
0.6
1.2
|
L
 -39.8%
H
0.6
3.2
|
L
 -94.9%
H
0.6
15.5
|
L
 -94.9%
H
0.6
15.5
|
L
 -94.9%
H
0.6
15.5
|
| Lexeo Therapeutics Inc |
|
401.2
|
4.9
|
L
 1.0%
H
4.8
5.0
|
L
 -2%
H
4.6
5.0
|
L
 16.4%
H
4.2
5.4
|
L
 8.7%
H
4.0
5.4
|
L
 -0.6%
H
4.0
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Cartesian Therapeutics Inc |
|
280.5
|
9.3
|
L
 1.6%
H
8.9
9.3
|
L
 -7.0%
H
8.8
10.6
|
L
 17.8%
H
7.8
10.9
|
L
 48.1%
H
5.8
11
|
L
 -9.6%
H
5.6
11
|
L
 -99.2%
H
5.6
1278
|
L
 -99.8%
H
5.6
4202.9
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
4.2
|
5.2
|
L
 -0.4%
H
5.2
5.4
|
L
 -10.6%
H
5.0
6.0
|
L
 -42.9%
H
5.0
9.9
|
L
 -71.2%
H
5.0
18.2
|
L
 -99.6%
H
5.0
2671.2
|
L
H
5.0
4991179.2
|
L
H
5.0
4991179.2
|
L
H
5.0
4991179.2
|
| Neurogene Inc |
|
772.4
|
38.6
|
L
 2.6%
H
36.6
39.4
|
L
 2.0%
H
35.3
39.8
|
L
 17.4%
H
30.6
42.0
|
L
 47.2%
H
24.9
43.7
|
L
 94.3%
H
15.9
43.7
|
L
 172.2%
H
6.9
74.5
|
L
 172.2%
H
6.9
74.5
|
L
 172.2%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,618.8
|
74.7
|
L
 0.5%
H
72.9
74.9
|
L
 -5.5%
H
72.1
79.2
|
L
 8.0%
H
69.6
81.0
|
L
 37.2%
H
53.2
81.0
|
L
 160.5%
H
28.3
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
| FibroBiologics Inc |
|
12.1
|
1.8
|
L
 2.8%
H
1.7
1.9
|
L
 21.5%
H
1.4
2.2
|
L
 129.1%
H
0.8
2.2
|
L
 69.2%
H
0.6
2.2
|
L
 -85.0%
H
0.6
12.4
|
L
H
0.6
1100
|
L
H
0.6
1100
|
L
H
0.6
1100
|
| Alto Neuroscience Inc |
|
1,395.1
|
35.6
|
L
 -2.3%
H
35.5
37.0
|
L
 -2.1%
H
34.0
37.4
|
L
 30.4%
H
27
37.5
|
L
 88.6%
H
17.9
37.5
|
L
 884.8%
H
3.4
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
| Fractyl Health Inc |
|
111.4
|
0.7
|
L
 1.5%
H
0.7
0.7
|
L
 -5.4%
H
0.6
0.8
|
L
 2.9%
H
0.6
0.8
|
L
 -7.9%
H
0.6
1.0
|
L
 -24.7%
H
0.4
2.4
|
L
H
0.4
15
|
L
H
0.4
15
|
L
H
0.4
15
|
| Kyverna Therapeutics Inc |
|
510.2
|
8.3
|
L
 -1.2%
H
8.2
8.4
|
L
 -4.5%
H
7.6
8.8
|
L
 9.9%
H
7.5
9.1
|
L
 5.5%
H
7.0
10.3
|
L
 121.8%
H
3.6
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
44.2
|
1.2
|
L
 0.9%
H
1.1
1.2
|
L
 -3.3%
H
1.1
1.2
|
L
 -3.3%
H
1.1
1.3
|
L
 -12.0%
H
1.1
1.4
|
L
 -34.6%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| NeOnc Tech Holdings Inc |
|
130.5
|
5.0
|
L
 5.0%
H
4.7
5.2
|
L
 9.4%
H
4.5
5.2
|
L
 45.4%
H
3.1
5.8
|
L
 15.6%
H
3
5.8
|
L
 -30.1%
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
L
H
3
13.0
|
| LENZ Therapeutics Inc |
|
187.3
|
6.0
|
L
 2.2%
H
5.6
6.0
|
L
 23.9%
H
4.7
6.0
|
L
 19.2%
H
4.5
6.7
|
L
 -15.0%
H
4.5
7.4
|
L
 -84.8%
H
4.5
50.4
|
L
 -76.1%
H
4.5
50.4
|
L
 -76.1%
H
4.5
50.4
|
L
 -76.1%
H
4.5
50.4
|
| Boundless Bio Inc |
|
65.3
|
2.9
|
L
H
2.9
2.9
|
L
 0.4%
H
2.8
2.9
|
L
 11.7%
H
2.6
3.2
|
L
 99.3%
H
1.4
3.2
|
L
 149.6%
H
1.0
3.2
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
628.3
|
16.7
|
L
 -5.0%
H
16.5
17.7
|
L
 -3.2%
H
15.8
17.8
|
L
 4.8%
H
14.1
17.8
|
L
 33.8%
H
11.2
17.8
|
L
 57.8%
H
8.6
17.8
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
555.0
|
8.4
|
L
 12%
H
7.4
8.4
|
L
 14.1%
H
6.3
8.4
|
L
 29.0%
H
6.3
8.4
|
L
 32.7%
H
5.6
8.4
|
L
 55.6%
H
5.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
23.2
|
3.3
|
L
 9.4%
H
3.1
3.5
|
L
 -19.0%
H
2.8
4.2
|
L
 11.7%
H
2.7
4.3
|
L
 -45.2%
H
2.6
6.5
|
L
 17.3%
H
1.9
6.9
|
L
 -61.0%
H
0.6
9.5
|
L
 -61.0%
H
0.6
9.5
|
L
 -61.0%
H
0.6
9.5
|
| Inhibrx Biosciences Inc |
|
1,783.3
|
121.2
|
L
 -0.9%
H
120.5
124.2
|
L
 -2.2%
H
119.4
129.9
|
L
 46.5%
H
80.4
131.0
|
L
 27.3%
H
77.5
131.0
|
L
 335.9%
H
26.2
155.3
|
L
 882.7%
H
12.2
155.3
|
L
 882.7%
H
12.2
155.3
|
L
 882.7%
H
12.2
155.3
|
| Rapport Therapeutics Inc |
|
2,196.0
|
45.8
|
L
 -4.0%
H
45.5
48
|
L
 -10.0%
H
45.5
50.7
|
L
 12.2%
H
40.7
52.9
|
L
 23.7%
H
33.5
52.9
|
L
 204.3%
H
14.1
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
| Artiva Biotherapeutics Inc |
|
547.1
|
11.2
|
L
 0.6%
H
10.9
11.3
|
L
 -6.3%
H
10.9
11.8
|
L
 4%
H
10.4
12.3
|
L
 60.6%
H
6.7
12.3
|
L
 251.9%
H
2.2
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
2,972.4
|
61.7
|
L
 0.5%
H
60.6
62.7
|
L
 -7.0%
H
58.8
66.1
|
L
 -4.2%
H
58.8
72.6
|
L
 105.4%
H
28
72.6
|
L
 328.6%
H
9.6
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
| BioAge Labs Inc |
|
440.2
|
9.6
|
L
 1.0%
H
9.4
9.8
|
L
 -4.9%
H
9.2
10.3
|
L
 -11.0%
H
9.2
11.9
|
L
 -40.2%
H
8.7
26.0
|
L
 102.3%
H
4.6
26.0
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| Voyager Acq Corp (Class A) |
|
55.7
|
1.8
|
L
 15.0%
H
1.5
2.0
|
L
 22.2%
H
1.3
2.0
|
L
 -3.8%
H
1.3
2
|
L
 -82.0%
H
1.3
27.4
|
L
 -83.2%
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
| OnKure Therapeutics Inc (Class A) |
|
145.0
|
3.6
|
L
 0.6%
H
3.5
3.6
|
L
 -6.5%
H
3.4
4.0
|
L
 -11.0%
H
3.4
4.5
|
L
 -14.8%
H
3.4
4.8
|
L
 26.5%
H
2.2
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.4
|
L
 -1.8%
H
4.3
4.6
|
L
 6.5%
H
3.7
4.6
|
L
 4.8%
H
3.7
6
|
L
 5.8%
H
2.9
6
|
L
 212.8%
H
1.4
7.8
|
L
 91.7%
H
1.3
7.8
|
L
 91.7%
H
1.3
7.8
|
L
 91.7%
H
1.3
7.8
|
| Upstream Bio Inc |
|
329.2
|
6.0
|
L
 -1.2%
H
6.0
6.2
|
L
 -11.5%
H
5.8
7.0
|
L
 -6.4%
H
5.8
7.7
|
L
 -21.2%
H
5.8
8
|
L
 -70.0%
H
5.8
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Septerna Inc |
|
1,715.4
|
36.8
|
L
 -0.1%
H
36.6
37.6
|
L
 -9.2%
H
36.5
40.9
|
L
 5.1%
H
35.6
51.1
|
L
 20.3%
H
30.1
51.1
|
L
 161.0%
H
13.7
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
| Polyrizon Ltd |
|
23.4
|
11.2
|
L
 -10.5%
H
11
12.7
|
L
 -12.2%
H
11
15.3
|
L
 6.1%
H
9.1
15.3
|
L
 -16.5%
H
9.1
16.5
|
L
 78.4%
H
2.9
18.2
|
L
H
2.9
7200
|
L
H
2.9
7200
|
L
H
2.9
7200
|
| Medicus Pharma Ltd |
|
10.7
|
0.2
|
L
H
0.2
0.2
|
L
 -37.0%
H
0.2
0.3
|
L
 -43.3%
H
0.2
0.4
|
L
 -52.8%
H
0.2
0.5
|
L
 -91.5%
H
0.2
3.1
|
L
 -97.5%
H
0.2
8.9
|
L
 -97.5%
H
0.2
8.9
|
L
 -97.5%
H
0.2
8.9
|
| Telix Pharma Ltd (ADR) |
|
4,057.0
|
11.9
|
L
 1.7%
H
11.8
12.0
|
L
 4.9%
H
10.8
12.0
|
L
 19.2%
H
10.2
12.5
|
L
 36.2%
H
9.1
12.5
|
L
 27.6%
H
6.3
12.5
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
2,265.5
|
157.2
|
L
 1.1%
H
153.0
157.5
|
L
 4.6%
H
143.5
157.5
|
L
 11.7%
H
135.3
160.5
|
L
 36.2%
H
100
161.4
|
L
 193.9%
H
51.5
161.4
|
L
 1056.2%
H
11.2
161.4
|
L
 1056.2%
H
11.2
161.4
|
L
 1056.2%
H
11.2
161.4
|
| Zhengye biotech Holding Ltd |
|
76.3
|
1.6
|
L
 -1.2%
H
1.6
1.7
|
L
 -8.5%
H
1.6
1.8
|
L
 21.1%
H
1.2
4.3
|
L
 101.3%
H
0.6
8.0
|
L
 -83.5%
H
0.6
11.5
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
| Sionna Therapeutics Inc |
|
324.6
|
7.2
|
L
 6.4%
H
6.6
7.2
|
L
 18.5%
H
5.8
7.6
|
L
 -85.4%
H
4.0
55.0
|
L
 -80.4%
H
4.0
55.0
|
L
 -70.8%
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
| Zenas Biopharma Inc |
|
2,143.0
|
32.9
|
L
 -0.1%
H
32.4
33.3
|
L
 0.8%
H
29.9
33.7
|
L
 5.6%
H
27.8
34.0
|
L
 89.0%
H
16.8
34.1
|
L
 91.8%
H
13.5
44.6
|
L
 214.0%
H
8.9
44.6
|
L
 214.0%
H
8.9
44.6
|
L
 214.0%
H
8.9
44.6
|
| Advanced Biomed Inc |
|
15.4
|
9.3
|
L
 -0.6%
H
9.1
9.4
|
L
 -2.4%
H
8.7
10.8
|
L
 22.7%
H
6.1
10.8
|
L
 112.8%
H
3.7
24.2
|
L
 3.8%
H
3.6
24.2
|
L
H
3.6
82
|
L
H
3.6
82
|
L
H
3.6
82
|
| Caris Life Sciences Inc (Class A) |
|
7,084.7
|
25.1
|
L
 -1.0%
H
24.5
25.1
|
L
 -5.0%
H
23.6
26.8
|
L
 53.6%
H
15.9
28.3
|
L
 62.0%
H
15.1
28.3
|
L
 -31.9%
H
14.2
36.8
|
L
 -10.5%
H
14.2
42.5
|
L
 -10.5%
H
14.2
42.5
|
L
 -10.5%
H
14.2
42.5
|
| Propanc Biopharma Inc |
|
2.3
|
1.0
|
L
 -1.0%
H
1.0
1.1
|
L
 -54.7%
H
1.0
1.9
|
L
 -3.8%
H
1.0
4.1
|
L
 -38.4%
H
1.0
6.8
|
L
 -98.4%
H
1.0
65
|
L
 -98.6%
H
1.0
234
|
L
 -98.6%
H
1.0
234
|
L
 -98.6%
H
1.0
234
|
| SpyGlass Pharma Inc |
|
968.0
|
28.9
|
L
 -0.2%
H
28.0
29.2
|
L
 7.5%
H
25.3
29.3
|
L
 27.6%
H
22.5
29.3
|
L
 55.9%
H
17.1
29.3
|
L
 9.6%
H
17.1
30.6
|
L
 9.6%
H
17.1
30.6
|
L
 9.6%
H
17.1
30.6
|
L
 9.6%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
777.1
|
15.8
|
L
 6.4%
H
14.5
15.9
|
L
 14.0%
H
12.6
15.9
|
L
 16.7%
H
12.6
15.9
|
L
 31.5%
H
8.8
17.8
|
L
 7.7%
H
8.8
17.8
|
L
 7.7%
H
8.8
17.8
|
L
 7.7%
H
8.8
17.8
|
L
 7.7%
H
8.8
17.8
|
| Generate Biomedicines Inc |
|
2,103.7
|
16.4
|
L
 0.3%
H
16.0
16.6
|
L
 3.9%
H
14.7
16.8
|
L
 14.3%
H
13.0
22.7
|
L
 27.0%
H
12.2
22.7
|
L
 29.6%
H
11
22.7
|
L
 29.6%
H
11
22.7
|
L
 29.6%
H
11
22.7
|
L
 29.6%
H
11
22.7
|
| Atrium Therapeutics Inc |
|
242.7
|
14.2
|
L
 -2.8%
H
14.0
14.7
|
L
 1.5%
H
13.1
14.7
|
L
 25.2%
H
11.4
14.7
|
L
 16.6%
H
11.1
14.7
|
L
 -3.8%
H
11.1
16.8
|
L
 -3.8%
H
11.1
16.8
|
L
 -3.8%
H
11.1
16.8
|
L
 -3.8%
H
11.1
16.8
|
| Jatt II Acquisition Corp |
|
95.2
|
12.2
|
L
 -0.4%
H
12
12.3
|
L
 1.6%
H
11.8
12.5
|
L
 1.2%
H
11.5
23.8
|
L
 17.0%
H
10.3
23.8
|
L
 16.2%
H
10
23.8
|
L
 16.2%
H
10
23.8
|
L
 16.2%
H
10
23.8
|
L
 16.2%
H
10
23.8
|
| Kailera Therapeutics Inc |
|
2,104.1
|
16.2
|
L
 3.1%
H
15.6
16.4
|
L
 -12.4%
H
15.2
18.3
|
L
 -6.3%
H
15.2
19.5
|
L
 -27.5%
H
15.2
23.8
|
L
 -37.6%
H
15.2
28.2
|
L
 -37.6%
H
15.2
28.2
|
L
 -37.6%
H
15.2
28.2
|
L
 -37.6%
H
15.2
28.2
|
| Alamar Biosciences Inc |
|
2,137.3
|
30.8
|
L
 0.8%
H
29.8
31.1
|
L
 -6.7%
H
29.2
33.5
|
L
 13.8%
H
26.2
38.5
|
L
 47.1%
H
19.2
38.5
|
L
 40%
H
18.8
38.5
|
L
 40%
H
18.8
38.5
|
L
 40%
H
18.8
38.5
|
L
 40%
H
18.8
38.5
|
| LakewoodAmedex |
|
4.5
|
1.9
|
L
 -1.1%
H
1.9
2.0
|
L
 -24.5%
H
1.9
2.9
|
L
 -13.0%
H
1.9
2.9
|
L
 -70.9%
H
1.7
7.8
|
L
 -97.8%
H
1.7
94
|
L
 -97.8%
H
1.7
94
|
L
 -97.8%
H
1.7
94
|
L
 -97.8%
H
1.7
94
|
| Hemab Therapeutics Holdings |
|
2,074.5
|
44.4
|
L
 0.1%
H
43.3
45.5
|
L
 -10.3%
H
42.7
49.4
|
L
 -1.3%
H
42.7
55.4
|
L
 69.7%
H
23.8
55.4
|
L
 30.6%
H
23
55.4
|
L
 30.6%
H
23
55.4
|
L
 30.6%
H
23
55.4
|
L
 30.6%
H
23
55.4
|
| Odyssey Therapeutics Inc |
|
1,382.2
|
28.8
|
L
 8.9%
H
25.7
29.1
|
L
 10.7%
H
22.9
29.1
|
L
 58.6%
H
18.0
29.1
|
L
 72.3%
H
15.1
29.1
|
L
 75.2%
H
15.1
29.1
|
L
 75.2%
H
15.1
29.1
|
L
 75.2%
H
15.1
29.1
|
L
 75.2%
H
15.1
29.1
|
| Lakefront Biotherapeutics NV |
|
1,865.7
|
28.5
|
L
 -1.8%
H
28.4
29.0
|
L
 -3.2%
H
28.3
29.5
|
L
 6.5%
H
25.7
29.9
|
L
 3.6%
H
25.7
30.9
|
L
 -0.4%
H
25.7
30.9
|
L
 -0.3%
H
25.7
30.9
|
L
 -0.3%
H
25.7
30.9
|
L
 -0.3%
H
25.7
30.9
|
| Conexeu Sciences Inc |
|
133.0
|
5.0
|
L
 -5.7%
H
4.9
5.6
|
L
 -29.4%
H
4.9
7.4
|
L
 -36.0%
H
4.9
10.5
|
L
 -70.5%
H
4.9
17.5
|
L
 -62.0%
H
4.9
18.8
|
L
 -62.0%
H
4.9
18.8
|
L
 -62.0%
H
4.9
18.8
|
L
 -62.0%
H
4.9
18.8
|
| Veraxa Biotech AG |
|
248.9
|
1.8
|
L
 15.0%
H
1.5
2.0
|
L
 22.2%
H
1.3
2.0
|
L
 -3.8%
H
1.3
2
|
L
 -92.9%
H
1.3
26.0
|
L
 -92.9%
H
1.3
26.0
|
L
 -92.9%
H
1.3
26.0
|
L
 -92.9%
H
1.3
26.0
|
L
 -92.9%
H
1.3
26.0
|
| Kardigan Inc |
|
1,949.6
|
20.9
|
L
 0.5%
H
20.5
21.4
|
L
 0.2%
H
19.4
22.5
|
L
 4.4%
H
19.4
23.1
|
L
 -5.2%
H
19.4
27
|
L
 -5.2%
H
19.4
27
|
L
 -5.2%
H
19.4
27
|
L
 -5.2%
H
19.4
27
|
L
 -5.2%
H
19.4
27
|
| Braveheart Bio Inc |
|
1,145.1
|
26.7
|
L
 1.8%
H
25.4
27.5
|
L
 -4.0%
H
24.3
29.2
|
L
 -10.3%
H
24.3
32
|
L
 -10.3%
H
24.3
32
|
L
 -10.3%
H
24.3
32
|
L
 -10.3%
H
24.3
32
|
L
 -10.3%
H
24.3
32
|
L
 -10.3%
H
24.3
32
|
| BioStem Technologies Inc |
|
66.2
|
3.7
|
L
 2.8%
H
3.6
3.9
|
L
 -3.6%
H
3.4
4.1
|
L
 -9.3%
H
2.3
4.2
|
L
 -9.3%
H
2.3
4.2
|
L
 -9.3%
H
2.3
4.2
|
L
 -9.3%
H
2.3
4.2
|
L
 -9.3%
H
2.3
4.2
|
L
 -9.3%
H
2.3
4.2
|
| Vogenx Inc |
|
471.4
|
31.7
|
L
 -1.3%
H
31.6
34
|
L
 -5.7%
H
29.0
34.6
|
L
 144.1%
H
13
35.5
|
L
 144.1%
H
13
35.5
|
L
 144.1%
H
13
35.5
|
L
 144.1%
H
13
35.5
|
L
 144.1%
H
13
35.5
|
L
 144.1%
H
13
35.5
|